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Abstract

The E26 transformation-specific transcription factors (ETS) PU.1 and Spi-B are
required for the earliest stages of B cell maturation within the bone marrow. PU.1 expression
is first detected in hematopoietic stem and progenitor cells (HSPCs), whereas Spi-B levels
begin to increase as early as the Pro-B cell stage. The expression levels of both factors are
maintained as B cells progress in development, and the lack of PU.1 and Spi-B at early stages
impairs B cell development and can lead to B cell leukemia. The mechanisms by which PU.1
and Spi-B control B cell development progression and prevent leukemogenesis have not been
completely elucidated. The work described in this thesis had two specific aims: 1) to determine
the requirement and function of PU.1 and Spi-B transcription factors in developing B cells and
2) to determine the requirement of these transcription factors in preventing leukemogenesis. It
was hypothesized that PU.1 and Spi-B control events associated with the transition from high
to low proliferative stages in B cell development and the absence of these factors favor a state
of proliferative stress leading to leukemogenesis. To assess this central hypothesis, we used a
mouse model in which Spi1 (encoding PU.1) was conditionally deleted in B cells by Cre
recombinase under control of the Mb1 gene in Spib (encoding Spi-B) deficient mice. We found
PU.1 and Spi-B were required in B cell development during the transition from Large to Small
Pre-B cells. Our data showed that at this transition, PU.1 functioned as an accessibility factor
for immunoglobulin light chain rearrangement, therefore enabling B cell maturation. In the
absence of these factors, B cell development was blocked at the Large Pre-B cell, and resulted
in the generation of B cell leukemia. We also determined that leukemogenesis in the absence
of Spi-B and PU.1 factors was associated with driver mutations in the Janus Kinases genes 1
and 3, conferring growth and survival advantages to these cells. We suggest that reactive
oxygen species (ROS) generation is a possible mechanism by which genetic damage arises,
consequently leading to B cell leukemia in the absence of Spi-B and PU.1. Collectively, this
thesis contributes to the elucidation of molecular mechanisms by which the complementary
transcription factors PU.1 and Spi-B coordinate B cell development and prevent
leukemogenesis.
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Chapter 1
1

Introduction
The immune system has evolved to protect organisms against pathogens that

ultimately have the potential to cause infections. Antigen-specific responses have only
become possible with the development of an intricate adaptive immune response, mostly
mediated by clonally diverse T and B lymphocytes. B lymphocytes, also known as B
cells, are distinguished by their ability to produce antigen-specific antibodies (Ab). This
ability confers memory to the immune system, allowing for a rapid and robust response
against previously exposed pathogens. Ab diversity is generated primarily during the
early stages of B cell development and is only achieved after successful rearrangement of
the immunoglobulin (Ig) genes. Effective generation of B cells requires an intricate
network of transcription factors that coordinate the passage through several
developmental stages. Disturbance of these stages can result in a failure to generate
mature B cells and, ultimately to the generation of B cell malignancies. The following
sections focus on the current understanding of B cell biology, including B cell subsets, B
cell development and processes leading to Ab diversity. In the final sections, B cellrelated malignancies such as leukemia and lymphoma are also addressed.

1.1

The Early Story of B Cells
In vertebrates, B cells play a central role in immunity to counter infections, cancer

and the development of auto-immune and inflammatory diseases. Despite their broad
importance to the generation of immune responses, the “discovery” of B cells and the
current understanding of B cell biology is a relatively recent focus of study. Abs,
produced by B cells through the rearrangement of the Ig genes, have long been known to
be important components of the humoral immune response. In 1965, the first
demonstration that B cells had different developmental origins than T cells came through
experiments in which the avian bursa of Fabricius was excised. These experiments
demonstrated a reduction in the production of plasma cells and antibodies, a condition
similar to that previously observed in X-linked agammaglobulinemia patients (M. D.
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Cooper, Peterson, & Good, 1965). A few years later, studies identified the bone marrow
(BM) in mammals to be the equivalent to the bursa of Fabricius in birds (M. D. Cooper
et al., 1966; Owen, Cooper, & Raff, 1974; Ryser & Vassalli, 1974). After these seminal
discoveries, researchers focused on elucidating the genetic origins of Ab diversity. The
process of somatic rearrangement, by which immunoglobulins genes rearranged to form
an Ab of unique specificity, was subsequently elucidated by Hozumi & Tonegawa in 1976
(Hozumi & Tonegawa, 1976). Later, recombination activating genes (RAG-1/2) were
demonstrated to mediate somatic rearrangement within the Ig locus (Oettinger, Schatz,
Gorka, & Baltimore, 1990; Schatz, Oettinger, & Baltimore, 1989). The sequential
rearrangement of the Ig genes, in conjunction with the expression of distinct, stagedependent cell surface markers, used to gradually uncover the developmental stages and
events governing B cell maturation (Hardy, 1991). Several transcription factors, including
PU.1, E2A, EBF-1 and PAX5 were demonstrated to be required for B cell lineage
commitment and developmental progression (Busslinger, 2004). These advances in
understanding of B cell maturation processes have contributed to human health, including
the development of vaccines, antibody based therapies and the understanding of genetic
altered pathways in B cell developmental diseases such as B cell acute lymphoblastic
leukemia (B-ALL).

1.2

B Cells, B Cell Subsets and Functions
B cells possess the unique capacity of rearranging Ig heavy (IgH) and light (IgL)

chain genes to produce and secrete Abs of unique antigen-specificity. Soluble Abs can
penetrate extracellular spaces and safeguard the organism against infections. The nonsecreted form of the Ab is expressed at the B cell surface as a membrane receptor known
as the B cell receptor (BCR). Despite their role in mediating humoral immunity, B cells
also contribute to cellular immune responses. B cells possess the ability to produce
cytokines; can activate T cells through antigen presentation; and also execute regulatory
functions which limit immune responses. In mammals, B cells originate from
hematopoietic stem/progenitor cells (HSPC) which are initially generated in the neonatal
fetal liver, and later in the BM after birth. Within the BM, immature B cells go through
several stages to obtain a BCR specific for nonself-antigen. Nonself-reactive immature B
cells exit the BM and complete their differentiation within the spleen, a stage which B
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cells are known as transitional B cells. Transitional B cells express IgM+ and IgD+ at the
cell surface, as well as high levels of the B cell activation factor receptor (BAFF-R),
which confers cell survival (Vigolo et al., 2018). The first antigen exposure of naïve B
cells occurs in the secondary lymphoid tissues. B cell activation leads to differentiation
into memory or plasma B cells that produce soluble Abs (Shinnakasu & Kurosaki, 2017).
Memory B cells develop in the germinal centers within secondary lymphoid organs and
express Ig isotypes other than IgM (IgG, IgA, or IgE) and do not express IgD. Reactivated
memory B cells can differentiate into plasma cells for a rapid response to an antigen.
Terminally differentiated plasma cells originate in the germinal centers of lymph nodes
or spleen, do not express Ig on the cell membrane and do not express the B cell marker
CD19 (K. Wang, Wei, & Liu, 2012). While some plasma cells are able to persist for years,
short-lived plasma cells remain in circulation for only days to weeks. The next section
focuses on the early developmental processes that B cells undergo within the BM, before
their egress to the spleen.

1.3

Bone Marrow B Cell Development
B cells originate from HSPC precursors within the BM after birth, as well as from

HSPCs precursors derived from neonatal fetal liver. Committed lymphoid precursors
(CLP) derived from HSPCs have the potential to generate either T or B cells (Ernst, 2009).
CLPs, can derive two main B cell progenitor subsets, which derive to distinct B cell
subsets: B-1 and B-2 B cells. While B-2 B cells, also known as conventional B cells, are
present in the secondary lymphoid organs and are considered to be the mediators of
adaptive immunity, B-1 B cells are part of the innate system and produce anti-microbial
natural antibodies (Montecino-Rodriguez & Dorshkind, 2012). B-1 cells develop and
mature within the BM and spleen however, Mature B-1 cells migrate to the serous cavities
later in development. For the purpose of this thesis, the development of B-2 B cells is
going to be emphasized. Five distinct developmental stages occur within the BM before
B cells reach maturation in the peripheral lymphoid organs. These stages, are
characterized phenotypically by the expression of cell surface molecules and by the status
of Ig rearrangement. As shown in Fig. 1.1A - the Pre-Pro-B stage represents a
heterogeneous population of cells which are not fully committed to the B cell fate. Stage
2 or the Pro-B cell stage, represents the first commitment step towards the B lymphoid
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lineage, although these cells still have the potential to develop towards the T cell lineage
upon loss of the transcription factor Pax5 (Rolink, Nutt, Melchers, & Busslinger, 1999).
At this stage, signaling through IL-7R is crucial for B cell proliferation and survival. The
rearrangement of the variable (V), diversity (D), joining (J) and constant (C) segments of
the IgH locus also occurs during this stage. Upon successful completion of IgH V(D)J
recombination, the Pre-B cell receptor (Pre-BCR) composed by IgH and surrogate light
chains is expressed at the cell surface. This event marks the transition to stage 3 or the
Pre-B cell stage. The Pre-B cell stage can be divided in two major subsets: Large Pre-B
cell and Small Pre-B cell stages. The Large Pre-B cells stage is characterized by rapid
cycling cells which are responsive to IL-7R signals. This enables expansion of the
population expressing a functional Pre-BCR (Clark, Mandal, Ochiai, & Singh, 2014).
Later on, Large Pre-B cells migrate to low IL-7 niches in the bone marrow. With lowered
IL-7, Large Pre-B cells differentiate into Small Pre-B cells and begin IgL chain
rearrangement. Once IgL chain is rearranged, the BCR is expressed on the cell surface,
marking the passage to stage 4 or the immature B cell stage. Immature B cells carrying a
nonself-reactive BCR egress from BM and home to the spleen to complete final
maturation as described above. Finally, mature naïve recirculating B cells can be found
in the BM and are characterized by high levels of B220 expression (Hardy, 1991).

1.3.1

“Hardy Scheme” of B Cell Development
The developmental stages described above can be characterized by the expression

of stage-specific cell surface markers. This enables the study of the specific stages of B
cell development by immunostaining. The scheme described by Hardy, characterizes
developing mouse B cells in six Fractions alphabetically labelled Fractions A, B, C, D, E
and F (Hardy, 1991). Developing B cells within Fractions A, B and C express B220 and
CD43 markers at the cell surface, while Fraction D, E and F lose CD43 expression (B220+
CD43-). CD43, also known as sialophorin, is a transmembrane cell surface protein which
is expressed in B cells, T cells, monocytes, neutrophils and platelets. Deficient expression
of CD43 is linked with X-chromosome-linked immunodeficiency disorder WiskottAldrich syndrome (Rosenstein et al., 1991). As CD43 expression is not restricted to B
cells, other cell surface markers are used to further distinguish the later B cell
development stages. Fractions A-C are further distinguished by differential expression of
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BP-1 and CD24. Thus, Fraction A cells (Pre-pro B cells) are classified as
B220+CD43+BP-1-CD24-; Fraction B (Pro-B cells), B220+ CD43+BP-1-CD24+ and
Fraction C (Large Pre-B cells), B220+CD43+BP-1+CD24+. During the later stages of
development, Fractions D-F are phenotypically distinguished by the lack of CD43
expression and the differentiated expression of B220 and IgM. Therefore, Fraction D
(Small Pre-B cells) are classified as B220+ (dull) CD43- IgM-; Fraction E (Immature B
cells), B220+ (dull) CD43- IgM+ and Fraction F (Mature recirculating B cells), B220+ (bright)
CD43- IgM+ (Fig. 1.1B).
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Figure 1.1. B Cell Development within BM and Maturation within Peripheral Lymphoid
Tissue.
(A) Stages of B cells development. Mature Naïve, Mature Activated, Short-Lived Plasma
Cells, Memory B Cells and Plasma Cells reside the peripheral lymphoid tissue. (B)
“Hardy Scheme” of B cell development. B cell developmental stages are distinguished
by differential expression of cell surface markers and the status of Ig rearrangement.
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1.3.2

The IL-7 Cytokine and IL-7 Receptor Signaling
Interleukin 7 (IL-7) is critical for supporting the development and homeostasis of

maturing T and B lymphocytes. IL-7 is produced by stromal cells within the bone marrow,
as well as fetal liver (Tokoyoda, Egawa, Sugiyama, Choi, & Nagasawa, 2004). CLP are
the first progenitor cells within the BM to express the IL-7R, a heterodimeric receptor
consisting of an IL-7 specific a chain and a common g chain (gc, encoded by Il2rg) shared
by the cytokine receptors for IL-2, IL-4, IL-9, IL-15, and IL-21 (Kondo, Weissman, &
Akashi, 1997). The earliest stages of B cell development seem to be dependent on IL-7R
signaling since IgM- cells express high levels of this receptor at the cell surface (Sudo et
al., 1993). Moreover, Pro-B cells migrate to IL-7 secreting sites within the BM (Tokoyoda
et al., 2004). IL-7-/- and IL-7R-/- knockout mice have illustrated the importance of this
cytokine for B and T cell development. While IL-7 knockout mice presented with
decreased numbers of B and T cells in the blood and a blockade in B cell development at
the Pro-B cell stage (von Freeden-Jeffry, 1995), IL-7R-/- knockout mice presented with a
strongly impaired phenotype and blockade in B cell development at the Pre-pro B cell
stage (Peschon et al., 1994). Although IL-7R signaling is essential for murine early B cell
development progression, the same requirement is not observed in human B cell
progenitors. Defective IL-7R in humans is associated with severe combined
immunodeficiency (SCID) characterized by a reduction in T cells, but not B cells or
natural killer (NK) cells, illustrating that IL-7R signaling is not required for the
development of B cells in humans (Puel, Ziegler, Buckley, & Leonard., 1998).
IL-7R does not possess intrinsic kinase activity. Upon IL-7 binding, Janus Kinase
1 and 3 (JAK1 and JAK3) which are constitutively associated with the IL-7Ra and IL2Rgc subunits, phosphorylate a tyrosine residue (Y449) in the IL-7Ra . Next, the Y449
phosphorylated site recruits signal transducer and activator of transcription 5A (STAT5A)
and STAT5B. Upon JAK-mediated phosphorylation of a conserved tyrosine at its C
terminus, STAT5 becomes activated and translocates to the nucleus where it binds to
DNA and activates transcription (Corfe & Paige, 2012). STAT5 leads to the activation of
Ccnd3 gene, encoding cyclin D-type 3, which has been demonstrated to be required for
pro and Pre-B cell proliferation. The D-type cyclins bind and activate cyclin-dependent
kinases 4 and 6, which phosphorylate the retinoblastoma protein (RB) leading to
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progression through the G1 phase of cell cycle (A. B. Cooper et al., 2006). IL-7R
signaling through STAT5 also induces the expression of the antiapoptotic B cell
lymphoma 2 (BCL-2) protein and induced myeloid leukemia cell differentiation protein
(MCL-1) encoded by Bcl2 and Mcl1 genes, respectively (Malin et al., 2010). The
phosphoinositide 3-kinase (PI3K)–AKT (PI3K-AKT) pathway is also activated upon IL7 stimulation (Corcoran et al., 1996). AKT phosphorylation by PI3K leads to degradation
of the forkhead box protein O (FOXO), which in turn lowers the levels of Bcl-2-like
protein 11, also known as BIM, a pro-apoptotic factor encoded by the Bcl2l11 gene (Clark
et al., 2014). BIM mediates B cell apoptosis upon IL-7 withdrawal. In the absence of IL7, B cell development is partially rescued upon loss of BIM (Huntington et al., 2009).
Altogether, IL-7R signaling activation has the capacity to stimulate proliferation and
survival in early B cell progenitors in mice (Fig. 1.2A, left).

1.3.3

Pre-BCR Checkpoint and Signaling
Highly proliferative Pro-B cells responding to IL-7R signaling are unable to

initiate the V(D)J rearrangement of IgH genes, since PI3K-AKT signaling induces
FOXO1 degradation, and FOXO1 is required to induce the expression of recombination
activating genes 1 and 2 (Rag1 and Rag2) (Amin & Schlissel, 2008). Because Ig
rearrangement involves the action of RAG-1 and RAG-2, which have the ability to
generate double-stranded breaks in the DNA, rearrangement during B cell development
is restricted to non-proliferative stages. However, cells at the Pro-B cell stage can
rearrange IgH chain genes as they migrate to sites in the BM with low IL-7, facilitating
IgH rearrangement (Tokoyoda et al., 2004). IL-7R expression levels are proportional to
the amount of phospho-STAT5 (Bertolino et al., 2005; Puel et al., 1998). In addition, ProB cells represent a heterogeneous population expressing different levels of IL-7R at the
cell surface (Bertolino et al., 2005; Puel et al., 1998). Collectively, these observations
explain some of the processes whereby highly proliferative cells can escape IL-7R
signaling, recombine IgH chain genes, and express the Pre-BCR at the cell surface.
The basic unit of the Pre-BCR molecule is composed of two identical IgH chains
and two invariant surrogate light chain proteins, l5 and VpreB (M. Zhang, Srivastava, &
Lu, 2004). Signaling through the Pre-BCR and BCR is dependent on the interaction with
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a Iga/Igb heterodimeric signaling complex (Fig 1.2A, right). Iga/Igb have intracellular
segments containing immunoreceptor tyrosine-based activation motifs (ITAMs) that
interact with downstream adaptor and effector molecules. Mice in which the
Iga/Igb complex has been abrogated present a strong block at the Pro-B cell stage,
characterized by the absence of B220+ CD43- cells in the BM, revealing the importance
of Pre-BCR signaling in the transition from Pro-B to Pre-B cell stages (Kraus et al., 2001).
Members of the Src family of tyrosine kinases (Src family) Blk, Lyn and Fyn,
which are assembled within the Pre-BCR and BCR structures, become activated after
receptor activation. Activated tyrosine kinases such as Syk, phosphorylate the adaptor
protein B cell linker (BLNK) allowing it to bind to phospholipase C-gamma2 (PLC-g2)
and the Bruton tyrosine kinase (Btk). Syk and Btk also phosphorylate a newly isolated
adaptor protein named B cell adaptor molecule for PI3K (BCAP). Phosphorylation of
both adaptor proteins, Blnk and BCAP leads to activation of two major signaling
cascades: PLC-g2 and PI(3)K pathways (Kurosaki, 2011). Due the lack of an obvious PreBCR ligand, it is understood that intrinsic activity of the Pre-BCR is sufficient to induce
downstream signaling cascades required for B cell maturation (Lam, Kühn, & Rajewsky,
1997; Monroe, 2006). Nonetheless, potential Pre-BCR ligands have been identified in the
BM of humans and mice such as galectin-1 and heparan sulfate, respectively (Bradl,
Wittmann, Milius, Vettermann, & Jack, 2003; Gauthier, Rossi, Roux, Termine, & Schiff,
2002).
The function of molecules downstream of the Pre-BCR has been studied through
the generation of knockout mice ablated for of these effectors. Deletion of Blnk leads to
an incomplete block at transition from Pro-B to Pre-B cell stage. The few mature B cells
that are present in these mice are unresponsive to BCR crosslinking, suggesting further
impairment in transduction events (S. Xu et al., 2000). In a similar fashion, mice carrying
mutant Btk and CD40 demonstrated a reduced number of B cells in the spleen and lymph
nodes and an absence of mature B cells expressing IgMlow/ IgDhigh compared to wild-type
mice (Khan, 1997). Although mice demonstrated no major deficiencies in B cell
development in the BM, Lyn seemed to be required for later stages of B cell maturation,
since Lyn-deficient mice had reduced numbers of mature B cells in the GC (Lamagna,
Hu, DeFranco, & Lowell, 2014). Because deletion of Src had only a moderate impact on
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B cell development, it was assumed that these kinases had overlapping signaling
functions. In fact, the triple deficiency of Blk, Fyn and Lyn leds to more severe
impairments in B cell maturation, such as a reduction of Pro-B cells transiting to the PreB cell stage. The number of peripheral B cells was also decreased in these mice (Saijo et
al., 2003).
Several studies have also demonstrated the crucial requirement of Btk and the
adaptor protein Blnk, at the Pre-B cell stage transition stage. Double deletion of both Btk
and Blnk in B cells results in a drastic reduction of Igk and Igl transcripts and a blockade
at the Pre-B cell stage. These findings suggested that signaling through these proteins can
not only contribute towards the termination of Pre-B cell expansion, but also facilitate Ig
rearrangement (Kersseboom et al., 2003). It has also been observed that mice lacking Btk
and Blnk develop Pre-B cell leukemias, suggesting the role of these proteins as tumour
suppressors (Ta, De Haan, De Bruijn, Dingjan, & Hendriks, 2011). Altogether, these
studies demonstrate that expression and signaling through the Pre-BCR is required for
progression in B cell development and termination of proliferative events, consequently
facilitating transition from Large to Small Pre-B cell stage.
In recent years, the focus of attention has moved towards understanding the
regulatory circuits mediated by IL-7R and Pre-BCR signaling. Lowering IL-7/IL-7R
signaling is a requirement for IgL rearrangement, however the signaling through this
pathway mediates proliferation and survival at the early stages of B cell development.
This raised the question of how these cells survive upon IL-7 withdrawal. Experiments
demonstrated that the phosphorylation of ERK correlated with Pre-BCR expression at the
cell surface conferred the ability of these cells to proliferate in low IL-7 conditions,
revealing involvement of the ERK/MAP kinase pathway for the selective expansion of
Pre-BCR+ cells (Fleming & Paige, 2001).
As previously observed, the deletion of Btk and Blnk leads to a failure of IgL
recombination (Kersseboom et al., 2003), indicating that the Pre-BCR signaling is not
limited to controlling survival, but also plays a role in coordinating differentiation events
during B cell development. The PI(3)K pathway, activated in response to IL-7R
stimulation, was also activated in response to Pre-BCR activation. In a similar fashion,
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PI(3)K and PKB phosphorylate FOXO3A and FOXO1 factors leading them to
degradation, consequently decreasing Rag1 and Rag2 expression. The presence of Blnk
protein is crucial for attenuation of the PI(3)K pathway, consequently culminating in the
stabilization of RAG and IgL recombination (Herzog et al., 2008; Ramadani et al., 2010).
Once stabilized, FOXO1 is able to induce the expression of Blnk, Pax5 and Syk which
will antagonize the activation of the PI(3)K–AKT pathway. This self-reinforcing
network, favors induction of Rag genes and the attenuation of IL-7R signaling via
PI(3)K–AKT (Ochiai et al., 2012).
The transcription factors Spi-B and PU.1 are also involved in the Pro-B to Pre-B
cell transition. Double-deletion of these factors blocked B cell development and leads to
Pre-B cell leukemia (Christie et al., 2015). In fact, PU.1 and Spi-B are able to oppose IL7R dependent proliferation by regulating expression of the Btk and Blnk genes (Sokalski
et al., 2011). Overall, the balance between IL-7R and Pre-BCR signaling, specifically the
attenuation of IL-7R signals, is mandatory for Ig recombination, and consequently B cell
maturation.
Although attenuation of IL-7R signaling is required for B cell development
progression, IL-7R silencing was not sufficient to induce IgL rearrangement in Pre-B
cells. The generation of knockout Pre-B cells for IRF4 and IRF8 demonstrated the
importance of IRF4 for IgL recombination. IRF4 seems to preferentially bind and induce
Igk germline transcription, whereas attenuating IL-7 signals lead to a more potent
activation of Rag expression. Upon IL-7R signaling attenuation increase in histone
acetylation at the iEk enhancer was observed, indicating that a decrease in IL-7 signal is
required for Igk recombination (Johnson et al., 2008).
Investigating the mechanism by which IL-7R signaling attenuation facilitated Igk
recombination, Mandal et al demonstrated that STAT5, activated by JAK1 and JAK3
upon IL-7 stimulation, forms a tetrameric complex that binds to iEk and represses the Igk
locus by recruiting the histone methyltransferase EZH2 (Mandal et al., 2011). Therefore,
attenuation of IL-7 signaling relieved repression at the Igk locus, facilitating RAG1/2
accessibility for Ig recombination.
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In summary, signaling through the Pre-BCR plays several roles in the transition
from proliferative stages in B cell development into resting stages where differentiation
occurs. The functions executed by Pre-BCR signaling can be summarized in three main
points: 1) Pre-BCR signaling confers survival to developing B cells under IL-7 reduced
conditions; 2) Pre-BCR signaling through Blnk attenuates PI(3)K-AKT signals
downstream of IL-7R enabling the stabilization of FOXO1 and FOXO3A factors consequently leading to Rag expression; 3) attenuation of IL-7 signals is also crucial for
IgL locus recombination, since tetrameric STAT5 recruits the histone methyltransferase
EZH2, repressing chromatin and decreasing accessibility.
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Figure 1.2. IL-7R and Pre-BCR Signaling. Interplay of these Signals Enables B Cell
Development Progression.

(A) IL-7R signaling (left) and BCR signaling (right) and its respective signaling
pathways. (B) Antagonistic actions executed by IL-7 and BCR signaling during B cell
development at the Large Pre-B cell to Small Pre-B cell transition.
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Id3

1.3.4

Rearrangement of The Immunoglobulin (Ig) Genes
V(D)J recombination is a sequential event that takes place at the Pro-B cell stage

and later in development, at the Pre-B cell stage. V(D)J recombination was first described
by Hozumi & Tonegawa in 1976, when they demonstrated that V and C gene segments,
that exist at long distances within the genome get rearranged at the DNA level and then
transcribed into a single mRNA molecule (Hozumi & Tonegawa, 1976). The mechanisms
underlying this process were elucidated years later. The presence a cis-acting DNA
sequence, consisting in a palindromic heptamer (CACAGTG) and an AT-rich nonamer
separated by a spacer of either 12 or 23 bp flanking the variable (V) and constant (C)
segments was noted. This cis-acting DNA sequence is known as the recombination signal
sequences (RSSs), suggesting the concept that V(D)J recombinase is evolutionarily
conserved (Schatz et al., 1989; Tonegawa, 1983).
The V(D)J recombinase was determined to be the product of two genes,
recombination activating gene 1/2, (Rag1/Rag2) that work together to mediate Ig
recombination. V(D)J recombination was induced in mouse NIH3T3 fibroblasts, through
DNA transfer of a single lymphoid-specific locus, leading to the isolation and
identification of recombination activating gene 1, or RAG-1 (Schatz & Baltimore, 1988;
Schatz et al., 1989). The efficiency of V(D)J recombination was increased ~1000 fold,
when fibroblasts were also transfected with a gene adjacent to RAG-1, leading to the
identification of RAG-2 (Oettinger et al., 1990).
It has been recognized that V(D)J recombination occurs between two gene
segments with flanking recombination signal sequences (RSSs) that differ in the spacer
length (either by 12 or 23 bp) between the heptamer and nonamer. The process is initiated
by RAG binding and nicking of a RSS within a single RSS complex. Next, the RAG
proteins bind and nick the next RSS complex and catalyze a cleavage of both RSSs. These
reactions yield a pair of blunt, 5’-phosphorylated signal ends, and a pair of coding ends
that terminate in covalently sealed DNA hairpin structures. The coding ends are released
and the RSSs are retained in a signal end complex (SEC). Coding ends are rejoined and
DNA is repaired through the classical nonhomologous end joining (NHEJ) DNA repair
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pathway (Bassing, Swat, & Alt, 2002). This pathway involves proteins including Ku70,
Ku80, XRCC4, DNA Ligase IV and XLF that function in DNA repair, processing and
reorganization (Schatz & Swanson, 2011).
More recently, two major observations identified RAG as a potential danger to
the mouse genome: 1) RAG has the ability to bind to thousands off-target regions within
the genome and (Teng et al., 2015); and 2) RAG-mediated rearrangements are a common
feature of human leukemias harboring the ETV6-RUNX1 translocation (Papaemmanuil
et al., 2014). These independent observations brought forward the question whether B
cell leukemogenesis could be derived from RAG off-target actions. Despite the ability of
RAG to bind in several regions in the genome, substrates for RAG cleavage are
preferentially depleted at sites of RAG binding, therefore protecting the genome against
off-target RAG cleavage (Teng et al., 2015).

1.3.5

The Mouse Immunoglobulin Heavy Chain Locus
As discussed in the sections above, IgH rearrangement occurs at the Pro-B cell

stage and culminates with the expression of two identical IgH chains in association with
SLC chains. Further in B cell development, SLC are replaced by two identical light chains
at the immature B cell stage. The IgH locus has a complex genomic organization,
consisting in repeated sets of genes presenting high homology and of different types,
variable (V), diversity (D) and junction (J). These genes rearrange in a unique way
through the action of RAG-1 and RAG-2 to generate a highly variable repertoire of
expressed BCR or secreted antibodies able to bind to a vast repertoire of epitopes. The
mouse IgH chain locus is located on chromosome 12 (chr12:113,258,768 - 116,009,954)
and spans ~2,800 kb according GENCODE Version M16 (Ensembl 91). This locus is
constituted of 8-9 IgH constant genes, 4 IgH joining genes, 17-20 IgH diversity genes and
152 IgH variable genes (Lefranc, 2004). Sequential rearrangement of this locus occurs in
an ordered fashion in which DJ genes are rearranged first, following the subsequent
rearrangement between V genes to the DJ segment (Alt et al., 1984).
IgH enhancers have been described within the IgH locus and seem to play crucial
roles in V(D)J recombination as well as in class switch recombination. The IgH intronic
enhancer also known as IgH µ enhancer, was the first mammalian enhancer to be
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characterized (Banerji, Olson, & Schaffner, 1983; Gillies, Morrison, Oi, & Tonegawa,
1983). As previous studies have demonstrated, germline deletion of the IgH intronic
enhancer impairs VH to DJH rearrangement at the IgH locus and decrease µ0 germline
transcription, indicating an important role of this enhancer in chromatin accessibility for
VDJ rearrangement. Interestingly, deletion of the IgH intronic enhancer does not affect
somatic hypermutation of their IgH variable region genes (Perlot, Alt, Bassing, Suh, &
Pinaud, 2005). These findings suggested the existence of other regulatory regions within
the IgH locus. The second enhancer, the IgH 3’ enhancer, was discovered years later and
it is located in the 3’ of the C region of IgH locus (Pettersson, Cook, Brüggemann,
Williams, & Neuberger, 1990). Lately, experiments performed by various investigators
using DNase I hypersensitivity assays reveled a complex regulatory region (RR) located
downstream of Cα that is predicted to serve as a major regulator of the IgH locus. This
region contains an ~28 kb region comprising four enhancers and a ~12 kb region
containing CTCF and Pax5 binding sites (Birshtein, 2014). Several studies have shown
that this region is a major regulator of somatic hypermutation and class switch
recombination within the IgH locus (Le Noir et al., 2017).

1.3.6

The Mouse Immunoglobulin Light (Kappa and Lambda) Loci
At the Small Pre-B cell stage, developing B cells begin rearrangement of the IgL

chain locus. Similar to the IgH chain locus, the mouse IgL chain locus is highly complex.
The IgL chain locus is composed of two different loci: an immunoglobulin kappa chain
that is preferentially rearranged first during B cell development, and an immunoglobulin
lambda chain locus, which also undertakes rearrangement in case of unsuccessful kappa
chain rearrangement. A crucial difference between IgH and IgL loci is the lack of D
segments on the IgL locus, hence rearrangement within this locus occurs only between V
to J gene segments. The immunoglobulin kappa locus (Igk) in mouse is located on
chromosome 6 (chr6:67,555,636 - 70,726,754) covering about 3,200 kb in size. Igk is
constituted of 174 V gene segments, 5 J genes segments and a unique constant gene
segment resulting in 189 genes in total (Lefranc, 2004). Unlikely Igk locus, the mouse
immunoglobulin lambda chain (Igl), has simpler features and organization. This locus
is located on chromosome 16 (chr16:19,026,858 – 19,260,844), and only contains 3 V

18

gene segments, 5 J gene segments and 4 C gene segments, totalizing 12 gene segments
(Lefranc, 2004).
Genomic elements, such as enhancers, insulators and promoters, are known to act
in a cis-regulatory manner mediating accessibility of this locus for Ig rearrangement. In
the Igk locus, two important enhancers have been described: an intronic enhancer (iEk),
located between Jk-Ck segments; the second enhancer is located ~9 kb downstream of
Ck, and its known as 3’Ek enhancer (Meyer & Neuberger, 1989; Queen & Baltimore,
1983). Single deletion of this enhancer, impairs but does not abolish Vk-Jk rearrangement
(Gorman et al., 1996; Y. Xu, Davidson, Alt, & Baltimore, 1996). Strikingly, double
deletion of both enhancers results in the lack of Igk rearrangement, demonstrating the
crucial function of these enhancers mediating Vk-Jk rearrangement (Inlay, Alt, Baltimore,
& Xu, 2002). Following in the same fashion, the Igl locus also contains two enhancer
elements which were characterized by mapping the relative sensitivity to
deoxyribonuclease I (DNase I) digestion across the Igl locus. Two strong enhancers El24

and second a genomic region El3-1 have been characterized to date (Hagman, Rudin,

Haasch, Chaplin, & Storb, 1990).

1.4

Transcriptional Control of B Cell Development
Strict regulation of transcriptional activity is required to coordinate processes such

as proliferation or the recombination of Ig genes. This task is achieved by the regulated
action of transcription factors acting in a specific manner during B cell development. The
action of these transcription factors can be presented in different developmental stages
starting with B cell lineage specification and commitment until differentiation and
recombination of Ig genes (Fuxa & Skok, 2007). The generation of lymphoid progenitors
and B lymphocytes is dependent on signaling pathways mediated by IL-7R, c-Kit and
Flt3. The ablation of signaling through any of these receptors results in impaired
generation of B cell progenitors in the BM (Voßhenrich, Cumano, Müller, Di Santo, &
Vieira, 2003; Waskow et al., 2008; Waskow, Paul, Haller, Gassmann, & Rodewald,
2002). The transcription factors E2A (a helix- loop-helix protein) and EBF (early B cell
factor) are important B cell lineage choice determinants, coordinating the expression of
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B cell specific genes (Gyory et al., 2012; Shimamoto et al., 1995). However, without the
presence of the paired domain protein Pax5, B cells cannot fully commit to the B cell
lineage. The targeted deletion of Pax5 in mice allowed mature B cells from peripheral
lymphoid organs to dedifferentiate in vivo back to early uncommitted progenitors in the
bone marrow, and rescued T lymphopoiesis in the thymus of T-cell-deficient mice
(Cobaleda, Jochum, & Busslinger, 2007). Pax5 activates genes encoding proteins
downstream of Pre-BCR and BCR signaling including Cd19, Cd21 and genes encoding
transcription factor such as c-myb and Ebf-1 (Cobaleda, Schebesta, Delogu, & Busslinger,
2007). Pax5 in conjunction with E2a and Ebf-1 factors are also known to facilitate IgH
rearrangement (Fuxa, 2004). The transcription factors Ikaros and PU.1 are required for
the activation of the B cell lineage program and cell fate determination. PU.1
concentration is also known to determine the fate decision between myeloid or lymphoid
progenitors (DeKoter, 2000).

1.5

E26 Transformation Specific (ETS) Transcription Factors
The E26 Transformation Specific (ETS) transcription factors are master

regulators of developmental processes. Proteins belonging to this family have a conserved
DNA binding domain, known as the ETS-domain. The founding member of this family
Ets-1, was discovered as one of the two eukaryotic DNA sequences transduced by the
avian retrovirus E26. Genes sequences from Ets-1 and Myb are fused with the viral gag
gene forming the E26 oncogene. Therefore, the name of this family is derived from the
name of the avian erythroblastosis virus, E26, carrying the v-ets (“E twenty-six”)
oncogene (Nunn, Seeburg, Moscovici, & Duesberg, 1983). To date, nearly 30 members
of this family have been identified and implicated in physiological and pathological
processes. Largely, members of the ETS transcription factors family contain the ETSdomain which is able to recognize purine-rich core (GGAA/T) DNA sequences (Karim
et al., 1990). However, this family is sub-classified according to sequence similarities and
the presence of other conserved domains (Sharrocks, 2001). The Spi sub-family is
comprised of PU.1, Spi-B and Spi-C, which have broad actions in B myeloid and
lymphoid differentiation as well as in B cell functions. Spi-C is the least understood
amongst the members of this family, but studies indicate Spi-C as a negative regulator of
the murine B cell lineage and regulating the follicular B cell differentiation (DeKoter et
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al., 2010; S. K. H. Li, Solomon, Fulkerson, & DeKoter, 2015). In this thesis, we focused
our attention on members of the Spi sub-family of ETS transcription factors PU.1 and
Spi-B. Spi-B and PU.1 have high amino acid homology within the DNA binding and Nterminal activation domains rich in acidic amino acids (ACID). PU.1 contains a Gln-rich
(Q) region necessary for transactivation. The proline, glutamic acid, serine, and threonine
(PEST) sequence contained within PU.1 and Spi-B is known to interact with interferon
regulatory factor (IRF) family transcription factors, and is suggested to be involved with
protein degradation (Fig. 1.3) (Brass, Zhu, & Singh, 1999; Rogers, Wells, & Rechsteiner,
1986).
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Figure 1. 3 Transcription Factors PU.1 and Spi-B.
(A) DNA-binding sequence consensus for PU.1 and Spi-B. This example was generated
from genome-wide PU.1-binding sites in B cells. (B) Domains of mouse PU.1 and Spi-B
protein. Indicated are acidic, glutamine-rich (Gln), proline/glutamic acid/serine/threonine
(PEST), and DNA-binding (E26 transformation-specific, ETS) domains.
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Transcription Factor PU.11

1.5.1
1.5.1.1

Historical Background

PU.1 is a DNA-binding nuclear protein (transcription factor) that is a member of
the E26 transformation-specific (ETS) family. PU.1 was named because it can interact
with a “PU box,” a stretch of purines in the SV40 viral enhancer, that was identified as
being functionally active in lymphoid cells (Petterson & Schaffner, 1987). SPI1 was
independently identified as the protein product of a gene dysregulated in murine
erythroleukemia, as a consequence of proviral integration of the spleen focus-forming
virus (SFFV) (Moreau-Gachelin, Tavitian, & Tambourin, 1988). This gene/protein was
named SPI1 for “spleen focus-forming virus proviral integration site 1.” PU.1 and SPI1
were subsequently recognized to be the same protein (Goebl, 1990; Paul, Schuetze,
Kozak, Kozak, & Kabat, 1991). PU.1 is encoded by Spi1 on mouse chromosome 2 and
by SPI1 on human chromosome 11 (Van Cong et al., 1990). The presence of functional
PU boxes led to the identification of PU.1 as a transcription factor that could interact with
the immunoglobulin (Ig) kappa 3’enhancer (Pongubala & Atchison, 1991; Pongubala et
al., 1992), the Ig heavy chain intronic enhancer (Nelsen et al., 1993), and the CD11b
promoter (Hickstein, Baker, Gollahon, & Back, 1992). PU.1 was thereafter described to
interact with a number of lymphoid- and myeloid-specific promoters and enhancers
(Turkistany & DeKoter, 2011).

1.5.1.2

PU.1 Structure and Function

Mouse PU.1 protein has 272 amino acids and has high sequence identity to human
PU.1 (Klemsz, McKercher, Celada, Van Beveren, & Maki, 1990; Ray et al., 1992). PU.1
is a member of the ETS family that includes 28 members in humans (Hollenhorst,
McIntosh, & Graves, 2011). The ETS family is defined by high amino acid sequence
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homology within a helix-loop-helix DNA-binding domain located in the C-terminal
region of the protein (Fig. 1.3) (Kodandapani et al., 1996). PU.1 is most highly related
to Spi-B and Spi-C among the ETS family (Hollenhorst et al., 2011). Dissection of PU.1
activity using in vitro reporter assays identified an N-terminal acidic domain of 100 amino
acids, a centrally located proline/glutamic acid/serine/threonine (PEST) domain, and a
112-amino acid ETS domain (Fig. 1.3) (Klemsz & Maki, 1996; Klemsz et al., 1990). The
N-terminal 100 amino acids of PU.1 represent an activation domain that has been reported
to recruit transcriptional cofactors including retinoblastoma (Rb), TFIID (Hagemeier,
Bannister, Cook, & Kouzarides, 1993), and CREB-binding protein (CBP) (Yamamoto,
Kihara-Negishi, Yamada, Hashimoto, & Oikawa, 1999). Thus, PU.1 functions as a
transcriptional activator by recruitment of transcriptional co-activators and RNA
polymerase II components. PU.1 interacts as a monomer with an AGAA or
GGAA purine-rich core motif (Fig 1.3). However, PU.1 can also bind DNA cooperatively
with interferon regulatory factor (IRF4) or IRF8 transcription factors to recognize an
ETS-IRF

composite

element

(EICE)

that

has

the

consensus

sequence

GGAAgtGAAA (Brass et al., 1999; Escalante et al., 2002). Cooperative binding of DNA
with IRF4/ IRF8 requires interaction with serine 148 located in the PEST domain of PU.1
(Eisenbeis, Singh, & Storb, 1995). Another well-studied interaction is between PU.1 and
the regulator of erythroid cell fate GATA-1 (Nerlov, Querfurth, Kulessa, & Graf, 2000;
Rekhtman, Radparvar, Evans, & Skoultchi, 1999; P. Zhang et al., 2000). PU.1 protein
interacts with GATA-1 protein to impair the enforcement of erythroid cell fate by GATA1, whereas GATA-1 interaction with PU.1 protein impairs enforcement of myeloid cell
fate by PU.1 (Hoppe et al., 2016; Stopka, Amanatullah, Papetti, & Skoultchi, 2005).
Studies utilizing chromatin immunoprecipitation coupled with next-generation
sequencing (ChIP-seq) permitted genome-wide analysis of PU.1 interaction in four
hematopoietic lineages: erythroid (Wontakal et al., 2011), B lymphocyte (Heinz et al.,
2010; Schwickert et al., 2014; Solomon, Li, Piskorz, Xu, & DeKoter, 2015), T
lymphocyte (J. A. Zhang, Mortazavi, Williams, Wold, & Rothenberg, 2012), and
macrophage (Ghisletti et al., 2010; Heinz et al., 2010). These studies revealed that PU.1
interacts with transcription start sites, within gene bodies, and within intergenic regions.
PU.1- binding locations highly correlate with locations of predicted enhancers (Ghisletti
et al., 2010; Whyte et al., 2013). PU.1-binding locations highly correlate with locations

25

of activating histone modifications, including in T cells and erythroid cells where PU.1
functions as an antagonist of differentiation (Ghisletti et al., 2010; J. A. Zhang et al.,
2012) (Ghisletti et al., 2010; Wontakal et al., 2011; J. A. Zhang et al., 2012). In
macrophages, PU.1 binding is associated with nearly all enhancers marked by the
activating histone mark H3K4me1 (Ghisletti et al., 2010; Lara-Astiaso et al., 2014). PU.1
interaction with target sites in the genome may be an important first step for nucleosome
remodeling, facilitating binding of other transcription factors and cofactors (Ghisletti &
Natoli, 2013). In summary, PU.1 interaction with the consensus motif GGAA or AGAA at
transcription start sites and enhancers is associated with recruitment of transcriptional
cofactors and induction of activating histone modifications.

1.5.1.3

PU.1 Expression and Regulation
PU.1 is expressed in adipocytes (F. Wang & Tong, 2008) and in hematopoietic

cells (Hromas et al., 1993) (Fig. 1.4). PU.1 is expressed at high levels in macrophages
and at lower levels in B cells, and these differences are critically required to promote
either macrophage or B cell development in culture (DeKoter, 2000). To determine PU.1
levels during development, several laboratories generated reporter alleles for Spi1 using
cDNA encoding green fluorescent protein or yellow fluorescent protein “ knocked in” to
the Spi1 locus (Back, Allman, Chan, & Kastner, 2005; Hoppe et al., 2016; Nutt, Metcalf,
D’Amico, Polli, & Wu, 2005). These studies revealed that PU.1 is expressed at high levels
in hematopoietic stem cells and throughout the development of all myeloid lineages (Fig.
1.4). PU.1 expression is sharply downregulated during differentiation into
megakaryocyte-erythroid progenitors and during differentiation into T cells. PU.1
expression is reduced upon differentiation of lymphoid progenitors into B cell
progenitors. PU.1 continues to be expressed throughout all stages of B cells, although at
lower levels than macrophages, neutrophils, and dendritic cells, and is downregulated
upon differentiation into plasma cells (Back et al., 2005; Nutt et al., 2005) (Fig. 1.4). PU.1
expression is regulated by both transcriptional and posttranscriptional mechanisms.
Spi1 transcription is regulated by interaction of the promoter region with an upstream
regulatory element located at 14 kb relative to the transcription start site (Leddin et al.,
2011; Rosenbauer et al., 2004). Mutation of the 14 kb URE sequence led to reduced
Spi1 transcription in myeloid and B cells and increased PU.1 expression in T cells
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(Rosenbauer et al., 2006). The half-life of PU.1 protein allows for accumulation during
increased cell cycle length (Kueh, Champhekar, Nutt, Elowitz, & Rothenberg, 2013).
Finally, PU.1 expression is modulated by microRNA-155 in the B cell lineage. Mutation
of the gene-encoding miR-155, or mutation of the miR-155 target site in the 30 UTR of
the Spi1 gene, caused PU.1 expression to be upregulated in B cells (D. Lu et al., 2014;
Vigorito et al., 2007). In summary, PU.1 levels are regulated by transcription, by protein
stability, and by microRNAs.
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Figure 1. 4. PU.1 Levels Throughout Hematopoiesis.
Relative PU.1 levels are represented by intensity of the orange color within the diamond.
Cellular stages of hematopoiesis are indicated progressing from left to right. HSC
hematopoietic stem cell, MPP multipotent progenitor, MEP megakaryocyte-erythrocyte
progenitor, CMP common myeloid progenitor, LMPP lymphoid-primed multipotent
progenitor, GMP granulocyte-macrophage progenitor, MDP monocyte-dendritic cell
progenitor, CLP common lymphocyte progenitor, MkP megakaryocyte progenitor, EP
erythrocyte progenitor, CDP conventional dendritic cell progenitor, DCs dendritic cells,
Pro-B progenitor B cell, B-1 and B-2 major B cell subsets, ALP all lymphocyte
progenitor, ETP early thymic progenitor, pro-NK natural killer cell progenitor, NK
natural killer cell, pro-T progenitor T cell, CD4+ and CD8+ major T cell subsets
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1.5.1.4

Biological Function of PU.1

The biological function of PU.1 has been studied using genetically modified
mouse models. Descriptions of mice homozygous for germline null alleles of Spi1 were
published by Harinder Singh laboratory in 1994 (Scott, Simon, Anastasi, & Singh, 1994)
and Richard Maki’ s laboratory in 1996 (McKercher et al., 1996). The DeKoter laboratory
described mice homozygous for a hypomorphic allele of Spi1 in 2007 (DeKoter, Kamath,
& Houston, 2007). These studies showed that PU.1 was required to generate all white
blood cell lineages including B cells, T cells, granulocytes, and macrophages. Erythroid
and megakaryocyte development was largely normal in these mice. In order to determine
at what stage PU.1 was required for development, conditional knockout alleles of
Spi1 were described by three groups in 2005 (Iwasaki et al., 2005; Polli et al., 2005; Ye,
Ermakova, & Graf, 2005). These studies revealed that PU.1 was required to generate
myeloid and lymphoid progenitors. Spi1 deletion at any stage resulted in blocked myeloid
development (K. L. Anderson et al., 2000; Chopin et al., 2013; Iwasaki et al., 2005). After
commitment to the B cell lineage, PU.1 was not absolutely required for B cell
development, because PU.1 function was complemented by the related transcription
factor Spi-B. In the absence of both PU.1 and Spi-B, B cell development was arrested at
an early stage (Sokalski et al., 2011). PU.1 concentration plays key roles in regulation of
immune function. Upregulation of PU.1 expression in B cells, caused by mutation of the
gene-encoding miR-155 or by mutation of the miR-155 target site in the 3’UTR of the
Spi1 gene, led to defects in B - T cell interaction, impaired antibody-forming responses,
and impaired plasma cell differentiation (D. Lu et al., 2014; Vigorito et al., 2007).
In the T cell lineage, PU.1 expression was downregulated at the beta-selection
checkpoint during T cell development in the thymus (M. K. Anderson, Hernandez-Hoyos,
Diamond, & Rothenberg, 1999). However, PU.1 is upregulated in a peripheral T cell
population expressing interleukin-9 (IL-9). This population, known as T helper 9 (Th9)
cells, requires PU.1 for proper development and function (Chang et al., 2010). This group
showed that T helper cells are exquisitely sensitive to PU.1 concentration, as even low
levels of expression have major functional consequences for T helper cell development
(Awe et al., 2015).
PU.1 concentration plays an important role in regulating self-renewal of
hematopoietic stem cells (HSCs). Deletion of Spi1 in HSCs promotes premature cell cycle
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progression and consequently stem cell exhaustion (Staber et al., 2013; Will et al., 2015).
In contrast, increased expression of PU.1 in HSCs, induced by macrophage colonystimulating factor (M-CSF) signaling, opposed self-renewal and increased the frequency
of “choice” toward the myeloid cell fate (Mossadegh-Keller et al., 2013). Therefore, HSC
self-renewal is sensitive to PU.1 concentration. In general, high PU.1 levels promoted
increased differentiation and reduced self-renewal, while reduced PU.1 levels lead to
reduced differentiation and increased self-renewal. Taken together, these studies showed
that PU.1 levels are biologically important for development, differentiation, and selfrenewal of hematopoietic lineages.

1.5.1.5

Role of PU.1 in Disease

PU.1 has been associated with leukemia since its discovery. In 1988, researchers
first identified Spi1 as a gene recurrently disrupted in murine erythroleukemia by proviral
insertion of murine spleen focus-forming virus (SFFV) (Goebl, 1990; Moreau-Gachelin
et al., 1988). SFFV proviral integration resulted in overexpression of PU.1; and
overexpression of PU.1 was sufficient to induce erythroleukemia in mice (MoreauGachelin et al., 1996). In contrast, reduced levels of PU.1 in mice can cause B cell acute
lymphoblastic leukemia (B-ALL) and acute myeloid leukemia (AML). Mice that
developed AML as a consequence of gamma-irradiation had recurrent deletions or point
mutations of a 2Mbp region of chromosome 2 that included Spi1 (Cook et al., 2004). Mice
expressing 20% of normal levels of PU.1, as a consequence of deletion of an upstream
regulatory element (URE) located at 14 kb relative to the transcription start site,
developed myeloid leukemia at high incidence (Rosenbauer et al., 2006, 2004).
Interestingly, these mice also developed T cell lymphoma associated with increased levels
of PU.1 expression in the thymus (Rosenbauer et al., 2006). Reduced PU.1 levels led to
a preleukemic condition by increasing rates of proliferation and reducing differentiation
of hematopoietic stem cells and myeloid progenitor cells (Staber et al., 2013; Will et al.,
2015; Ziliotto et al., 2014). Even a modest 35% reduction in PU.1 expression strongly
cooperated with Msh2 homozygous mutation to promote abnormal proliferation of
myeloid cells leading to leukemia (Will et al; 2015). Restoration of PU.1 levels in AML
cells restored the monocyte-macrophage differentiation program and opposed continued
proliferation (Sive et al., 2016). In the B cell lineage, mutation of Spi1 led to B-ALL, but
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with low incidence and with long latency (S. H. M. Pang et al., 2016). However, mice
with deletions of genes encoding both PU.1 and Spi-B had impaired B cell development
and developed B cell acute lymphoblastic leukemia at 100% incidence by 21 weeks of
age (Sokalski et al., 2011). Thus, PU.1 and Spi-B function as complementary tumor
suppressors in the B cell lineage.
In summary, PU.1 is a tumor suppressor in the B cell and myeloid lineages but may
function as an oncogene in the erythroid and T cell lineages. These opposing findings
illustrate the importance of maintaining appropriate PU.1 levels throughout
hematopoietic development. Mutation of human SPI1 was not associated with
erythroleukemia or T cell leukemia, but was associated with human acute myeloid
leukemia (AML). PU.1 expression is repressed by the protein product of the RUNX1ETO translocation, one of the most frequent chromosomal abnormalities in AML
(Vangala et al., 2003). Reduced PU.1 levels are associated with MLL mutations in mixed
lineage leukemia (Lavallée et al., 2015). In one cohort of patients, inactivating mutations
of SPI1 were associated with AML (Mueller, 2003). These studies suggest that altered
levels of PU.1 protein in human cells contribute to leukemogenesis. PU.1 marks
superenhancers in B cells are associated with a wide variety of diseases (Whyte et al.,
2013). Alzheimer’ s disease was recently shown to be associated with upregulation of
immune response genes that are targeted by PU.1 (Gjoneska et al., 2015). These studies
indicate that perturbations in PU.1 levels are associated with cancer, B cell dysfunction,
and inflammation.
PU.1 is an ETS transcription factor that is highly expressed in hematopoietic cell
types, with expression highest in myeloid cells, lower in lymphocytes, and lowest in red
blood cells and megakaryocytes. PU.1 interacts with “PU boxes” in the genome to activate
transcription of target genes. Deletion of the gene encoding PU.1 results in multiple
hematopoietic defects including loss of development of myeloid cells and lymphoid cells.
Reduced PU.1 expression leads to impaired differentiation and increased proliferation of
HSCs, myeloid progenitor cells, and progenitor B cells. Even modestly reduced or
increased PU.1 expression can lead to leukemia and impaired immune function. Rapid
advances in next-generation sequencing will allow a better understanding of the
mechanisms by which deregulated levels of PU.1 lead to diseases such as leukemia. The
global identification of PU.1 target genes in myeloid and B cell progenitors, as well as
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the determination of genomic alterations found in leukemic cells, will enhance knowledge
of the molecular mechanisms of human leukemia.

1.5.2

Transcription Factor Spi-B

1.5.2.1

Historical Background & Structure and Function

The transcription factor Spi-B is the second member of the Spi subfamily of ETS
transcription factors. The Spi-B gene is located on chromosome 19 in humans and to
chromosome 7 in mice, and in humans it encodes a protein of 262 amino acids. This factor
was identified by screening a Burkitt lymphoma cDNA library with a human cDNA probe
corresponding to the DNA-binding region of the Spi-1 protein (Ray et al., 1992). Spi-B
has a DNA-binding domain at the C-terminus and an acidic N-terminal domain which
corresponds to the transactivation domain in PU.1. The human Spi-B protein shares 43%
amino acid sequence identity and 67% DNA-binding domain sequence identity with
human PU.1 (Fig 1.3) (Ray et al., 1992). Murine Spi-B and PU.1 share 70% sequence
homology in their DNA-binding domain (Chen et al., 1995). In addition, PU.1 and Spi-B
also bind to identical DNA- binding sequences and transactivate the same target genes in
vitro (Ray-Gallet, Mao, Tavitian, & Moreau-Gachelin, 1995; Su, 1996). Spi-B
transcription factor is less studied compared to the transcription factor PU.1.

1.5.2.2

Biological Function and Gene Regulation of Spi-B

Spi-B expression was first thought to be exclusive to B and T lymphocytes (Su,
1996), but recent studies have demonstrated that Spi-B is expressed in intestinal microfold
cells as well as plasmacytoid dendritic cells (pDCs) (Kanaya et al., 2012; Schotte, 2003).
Although its expression decreases in mature T cells, Spi-B expression increases as B cells
mature, suggesting a critical role for Spi-B in differentiated B cells (Su, 1996). Consistent
with its lineage-specific expression, Spi-B mRNAs are restricted to the lymphoid organs
of developing mouse embryos and adult mice (Su, 1996). Unlike PU.1 knockout mice,
germline Spi-B knockout are viable and possess mature B and T cells, despite the fact
that Spib-/- B cells have defects in functional and humoral responses (Su et al., 1997),
suggesting the involvement of Spi-B is in BCR-mediated responses. It is thought that the
less severe phenotype observed in Spi-B knockout mice is a consequence of Spi-B degree
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of complementary with PU.1, as both transcription factors recognize the same binding
sites (Ray et al., 1992) and can activate the same reporter gene constructs in vitro (Ray et
al., 1992; Su, 1996). In order to test that these transcription factors have complementary
functions, mice heterozygous for Spi1 were crossed to Spib-/- to generate Spi1+/- Spib-/mice (Garrett-Sinha et al., 1999), since complete PU.1 deletion resulted in embryonic
lethality (Scott et al., 1994). The double deletion of these factors, increased the severity
of the deficiencies observed in Spi-B knockout mice, such as the basal levels of apoptotic
cells, reduced BCR signaling, and impaired IgM and LPS-mediated B cell proliferation.
Therefore, Spi-B was required in mature B cells specifically for BCR transduction in a
complementary manner.
To test whether-B and PU.1 complementarity during B cell development, a bone
marrow specific mouse strain deleting Spi-B and PU.1 in Pre-B cells was generated by
crossing Spi-B germline knockout mice with mice in which PU.1 is conditionally deleted
in the bone marrow (Cd19+/Cre Spi1lox/lox) (Sokalski et al., 2011). While mice lacking one
of these factors resulted in only mild impairments in B cell development, mice lacking
both factors have a severe blockade in B cell development, reaffirming that these factors
function in a complementary manner (Sokalski et al., 2011). With the advance of next
generation sequencing methods, the existence of differential PU.1 and Spi-B binding sites
was investigated by chromatin immunoprecipitation followed by next generation
sequencing (ChIP-seq) in murine WEHI-279 lymphoma cells (Solomon et al., 2015).
PU.1 occupied 4528 regions and Spi-B occupied 3360 regions, with a high number of
overlapping regions occupied by both factors. Spi-B and PU.1 binding sites were
frequently located immediately upstream of genes associated with immune response and
activation of B cells. Motif-finding revealed that both transcription factors were
predominantly located at ETS motifs (5’ GGAA 3’), however, other unique motifs were
identified when examining regions associated with only one of the two factors. Motifs
associated with unique PU.1 binding included POU2F2, while unique motifs in Spi-B
regions contained a combined ETS-IRF motif (Solomon et al., 2015). In summary,
although Spi-B seems to have unique functions in BCR activation in mature B cells, most
of Spi-B function in B cell development seems to be complemented by PU.1 acting as a
safeguard guarantying the generation of mature B cells exiting the BM.
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1.6

B Cell Related Malignancies
Blood cancers originating from B lymphocytes are classified as B cell related

malignancies, also known as B cell neoplasms. B cell neoplasms originate from either B
cell precursors or from mature B cell subtypes. According to the World Health
Organization (WHO), B cell neoplasms can be classified in two major subtypes according
developmental stage of the cells involved: Precursor lymphoid B cell neoplasms and
mature B cell neoplasms. The classification of Leukemia versus Lymphoma is also used
to classify B cell neoplasms, classifying disease according to the level of BM or blood
involvement in the neoplasm. As an example, B cell acute lymphoblastic leukemia (BALL) is characterized as a neoplasm originating from of precursor lymphoid cells which
are committed to the B cell lineage. Since B-ALL is composed of Small to medium-sized
blast cells involving bone marrow and blood, this disease is further classified as leukemia.
The term lymphoma is used when the process is confined to a mass lesion with minimal
evidence of blood or marrow involvement. Therefore, precursor B cell neoplasms or
mature B cell neoplasms can be classified as either leukemia or lymphoma according with
the degree of marrow or blood involvement (Terwilliger & Abdul-Hay, 2017).
Acute Lymphoblastic Leukemia (ALL), including both subtypes originating from
T or B lymphocytes, primarily affects children <6 years, and corresponds to 75% of all
cancers diagnosed in children. Despite cure rates exceeding 90% in children, it remains
an important cause of morbidity and mortality in children and adults (Iacobucci &
Mullighan, 2017). The estimated annual incidence worldwide is 1- 475 cases per 100,000
population, with 6,000 new cases per year in the USA. The majority of the cases (8085%) are diagnosed as B-ALL subtype affecting males whereas lymphoblastic
malignancies of precursor T-cell type more often present as lymphoma, with mediastinal
masses. Male predominance is seen in lymphoblastic malignancies of both B cell and T
cell lineages (Canadian Cancer Society, 2018). Moreover, according to Canadian Cancer
Statistics, 3% of diagnosed cases of cancer in 2017 were leukemia, including subtypes
originated from lymphoid and myeloid cells (6,200 in 206,200). The Canadian Cancer
Statistics (2017) also showed that leukemia affects youth with an average age of incidence
of 15.5 years (Canadian Cancer Society, 2018). For the purposes of this thesis, we focused
our attention on B-ALL. To date, B-ALL is subcategorized in B cell lymphoblastic
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leukemia/lymphoma not otherwise specified (NOS) and B cell lymphoblastic
leukemia/lymphoma with recurrent genetic abnormalities.

1.6.1

B Cell Lymphoblastic Leukemia/Lymphoma Not Otherwise
Specified
Despite the fact that 75% of B-ALL harbor recurrent chromosomal alterations, a

Small percentage of B-ALL cases are associated with single-nucleotide polymorphisms
(SNVs) and DNA copy number alterations. Many genes containing structural alterations
are involved in lymphocyte development including PAX5, IKZF1, EBF1 and LMO2,
cell-cycle regulation and tumor suppression (CDKN2A/B, PTEN and RB1), lymphoid
signaling (BTLA, CD200, TOX and NR3C1), and transcriptional regulation and
coactivation (TBL1XR1, ETV6, and ERG) (Iacobucci & Mullighan, 2017). Children with
Down syndrome and other congenital diseases also have been reported to have increased
susceptibility to B-ALL (Antonarakis, 2017). These observations illustrate that even
Small non-recurrent mutations in genes harboring important regulatory functions in B
lymphocytes have the potential to lead to leukemogenesis.

1.6.2

B Cell Lymphoblastic Leukemia/Lymphoma with Recurrent
Genetic Abnormalities
Recurrent genetic alterations in B-ALL include aneuploidy and chromosomal

rearrangements that result in oncogene deregulation or expression of chimeric fusion
genes. Nine subtypes of B-ALL classified according a recurrent genetic abnormality.
1) B cell lymphoblastic leukemia/lymphoma with hypodiploidy, is a high-risk
leukemia that may be sub classified by degree of aneuploidy into near haploid
(NH-ALL, 24-31 chromosomes) and low hypodiploid (LH-ALL, 32-44
chromosomes) cases. Genomic analysis previously has shown that NH-ALL
has a high frequency of deletions and mutations that activate Ras signaling
(Holmfeldt et al., 2013). LH-ALL have high frequency of inactivating
alterations of the IKAROS genes IKZF2 (HELIOS) and IKZF3 (AIOLOS)
(Nachman et al., 2007). Therapeutically targeting the Ras pathway may
represent an important novel treatment outcome in this high-risk leukemia.
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2) B cell lymphoblastic leukemia/lymphoma with hyperdiploidy, is a type of
leukemia/lymphoma in which the neoplasm is committed to the B cell lineage
lymphoblast. These blasts contain >50 chromosomes (usually <66) and do not
present other structural alterations. B cell lymphoblastic leukemia/lymphoma
with hyperdiploidy is very common in children (about 25% of all B-ALL
cases) but also is frequent in adults (7%-8%) (Paulsson & Johansson, 2009).
3) B-lymphoblastic leukemia/lymphoma associated with t(9;22) (q34.1;q11.2) is
a neoplasm of lymphoblasts committed to the B cell lineage in which the blasts
present a translocation between BCR on chromosome 22 and the ABL1
oncogene on chromosome 9. This subtype of B-ALL accounts for 5% of all
pediatric B-ALL and 40% of adult ALL (Boer & den Boer, 2017).
4) B cell lymphoblastic leukemia/lymphoma with t(v;11q23) [MLL rearranged],
is a rare leukemia more common in children than in adults. It is similar to ALL
and acute myeloid leukemia with KMT2A rearrangements.
5) B cell lymphoblastic leukemia/lymphoma with t(12;21) (p13;q22)[ETV6RUNX1] translocation, is a neoplasm of committed B cell lymphoblast
precursors. The lymphoblasts show a translocation between ETV6 (also called
TEL) on chromosome 12 and RUNX1 (also called AML1) on chromosome
21. This leukemia is common in children, accounting for about 25% of cases
of B-ALL in that age group, but very rare in adults (Zuna et al., 2011).
6) B cell lymphoblastic leukemia/lymphoma with t(1;19) (q23;p13.3)[TCF3PBX1], harbors translocations is TCF3-PBX1 B-ALL. This leukemia presents
a translocation between TCF3 (also known as E2A) on chromosome 19 and
PBX1 (Alonso, 2013). It is a neoplasm of B-lymphoblasts and is relatively
common in children (6%) and less common in adults.
7) B-lymphoblastic

leukemia/lymphoma

(B-ALL/LBL)

with

t(5;14)

(q31.1;q32.1), is a leukemia subtype defined by the presence of lymphoblasts
committed to the B cell lineage in which the blasts harbor a translocation
between IL3 and IGH gene, resulting in variable eosinophilia. This is a rare
disease, accounting for < 1% of cases of ALL reported in children and adults.
8) B

cell

lymphoblastic

leukemia/lymphoma

with

intrachromosomal

amplification of chromosome 21 (iAMP21), corresponds to 2% of B-ALL.
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Patients presenting intrachromosomal amplification of chromosome 21
(iAMP21)., is defined by gain of at least 3 copies of the region of chromosome
21 containing RUNX1. The amplification is often large and complex and
accompanied by deletion of the subtelomeric regions of chromosome 21. It is
associated with poor outcome but the mechanisms of leukemogenesis are
unclear. iAMP21has increased risk of relapse (Mueller, 2006).
9) B cell lymphoblastic leukemia/lymphoma with translocations involving
tyrosine kinase cytokine receptors (‘BCR-ABL1–like ALL’): The Ph-like
ALL has a gene expression profile similar with BCR-ABL1-positive ALL but
lack the rearrangement BCR-ABL1. Among the common genomic features of
BCR-ABL1–like ALL are alterations of B-lymphoid transcription factor
genes (particularly IKZF1 deletions) and genetic alterations deregulating
cytokine receptor and tyrosine kinase signaling. 50% of the cases include
rearrangements and mutations of CRLF2, 12% rearrangements of ABL-class
tyrosine kinase genes, 7% JAK2, 11% mutations activating JAK-STAT
signaling and 6% Ras signaling (Jain et al., 2017).

1.6.3

Mouse Models for The Study of B Cell Related Malignancies
Due to the existence of many leukemia subtypes, the development of murine

models to study leukemia have been critical for the development of novel targeted
therapy. Although, the development of mouse models seems to be in critical demand,
currently only a few mouse models have been characterized and used for clinical
translation (Jacoby, Chien, & Fry, 2014) . To date, the experimental systems used to study
ALL are syngeneic models and xenografts, which have limitations since they cannot
mimic the host microenvironment required for leukemia development (Kohnken, Porcu,
& Mishra, 2017). Therefore, the development of spontaneous leukemia mouse model
featuring aspects of human disease has become important for the understanding of disease
biology as well for the development and testing of new target therapies for B cell
neoplasms.
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1.7

Central Hypothesis
The central hypothesis of this thesis is that Spi-B and PU.1 transcription factors

have redundant functions during B cell development, controlling events associated with
transition from high to low proliferative stages in B cell development, and that the absence
of these factors would favor a state of proliferative stress leading to leukemogenesis.

1.8

Thesis Overview
This thesis characterizes the role of the ETS transcription factors Spi-B and PU.1

in normal B cell development as well as into the mechanisms by which the absence of
these factors leads to leukemogenesis. Specifically, we elucidated the requirement of
these factors during B cell development and the mechanism by which Spi-B and PU.1
facilitate light chain rearrangement. Secondly, we determined that Spi-B and PU.1
absence is the ‘first hit’ for leukemogenesis, but that secondary driver mutations in genes
that confer survival and proliferative advantages is required for leukemia progression.
Finally, we provide preliminary insight into the potential mechanisms by which Pro-B
cells acquire a large number of mutations due to the lack of Spi-B and PU.1.
Both studies described in Chapter 2 and Chapter 3, were performed using a
conditional deletion mouse model, Mb1-CreΔPB, in which the Spib and Spi1 (encoding
Spi-B and PU.1) genes are deleted during early B cell development. This mouse model
facilitated the study of the role of these factors during the development of B cells, as well
as in leukemogenesis.

1.8.1.1

Chapter 2: PU.1 Regulates Ig Light Chain Transcription and
Rearrangement in Pre-B Cells During B Cell Development

In Chapter 2, we demonstrated a crucial requirement for Spi-B and PU.1
transcription factors during B cell development at the transition from Large Pre-B cells
(Fraction D) to Small Pre-B cells (Fraction E). At this transition, developing B cells
rearrange immunoglobulin light chain genes expressed in the B cell receptor. The absence
of Spi-B and PU.1 in vivo blocked the progression of developing B cells in the bone
marrow at the Large Pre-B to Small Pre-B cells stage. PU.1 ChIP-seq combined with
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RNA-seq in Pro-B cells in which PU.1 expression was restored by a doxycycline
inducible-system, demonstrated that PU.1 binds to the variable genes within the
immunoglobulin kappa locus and alters mRNA transcription. Forced PU.1 expression in
this cell line leads to the rearrangement of the immunoglobulin light chain in conditions
with low IL-7. Finally, we demonstrated that the level of transcription from the
immunoglobulin kappa chain locus is reduced ex vivo in Small Pre-B cells derived from
mice lacking Spi-B and PU.1, suggesting a role of these factors in the accessibility of this
locus.

1.8.1.2

Chapter 3: Deletion of Genes Encoding PU.1 And Spi-B Leads
to B Cell Acute Lymphoblastic Leukemia Associated with Driver
Mutations in Janus Kinases

In Chapter 3, we focused our attention on understanding the mechanisms by which
the absence of Spi-B and PU.1 in developing B cells results in B cell acute lymphoblastic
leukemia (B-ALL) with a latency period of 18 weeks. We performed RNA and wholeexome sequencing (WES) analyses in leukemias from mice lacking Spi-B and PU.1 in
developing B cells aiming to identify secondary driver mutations of leukemogenesis. We
found a large number of single-nucleotide variants (SNVs) present in the leukemias – the
majority of which resulted in amino acid changes and in the gain of early stop-codons.
Integration of RNA-seq and WES revealed the potential for IKZF3, JAK1 and JAK3
mutations to act as secondary drivers of leukemogenesis, since these genes are often
mutated and highly expressed in mouse leukemias. Further analyses showed that
mutations found within the Jak3 gene resulted in amino acid substitutions located in the
pseudo-kinase (R653H, V670A) and in the kinase (T844M) domains. Finally, we
observed that these mutations confer survival and growth advantage to wild-type Pro-B
cells. We conclude that absence of Spi-B and PU.1 leads to leukemogenesis in association
with secondary driver mutations in JAK3.
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1.8.1.3

Chapter 4: Genetic Signatures of Leukemias Derived From PU.1
and Spi-B Knockout Mice Reveals Potential Etiology of The
Disease

In Chapter 4, we further investigated the etiology of leukemogenesis in the
absence of Spi-B and PU.1. Mutational signature analysis revealed an enrichment of C•G
> A•T genomic transversions in leukemias generated as a consequence of the lack of SpiB and PU.1. This type of signature has been recently observed in a Small proportion of
leukemias and is proposed to be caused as a result of guanine damage that is repaired by
a transcription-coupled nucleotide-excision repair pathway. A common type of guanine
damage is the 8-oxoguanine (8-oxoG) lesion, that is often caused by oxidative stress. We
examined the expression of DNA glycosylases, which are known to correct this type of
lesion, in RNA-seq data performed in six different leukemias extracted from Mb1-DPB
mice. We observed a modest increase in expression of Mutyh and Neil1 genes in mouse
leukemias, which suggests the possible involvement of nucleotide-excision repair
pathway in the repair of 8-oxoG lesions. Furthermore, our data also suggested that this
damage is caused by oxidative stress since gene expression encoding glutathione
peroxidase 1, Gpx1 and glutathione reductase Gsr were reduced in the RNA-seq data
from Mb1-DPB leukemias. These preliminary data suggest that leukemia cells in the
absence of Spi-B and PU.1 have impaired antioxidant mechanisms. These interesting
findings led us to hypothesize that overload of ROS leads to 8-oxoG damage resulting in
C•G > A•T mutational signature observed in leukemias in the absence of Spi-B and PU.1.
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Chapter 2
2

PU.1 Regulates Ig Light Chain Transcription and
Rearrangement in Pre-B Cells During B Cell
Development2
B cell development and Ig rearrangement are governed by cell type and

developmental stage–specific transcription factors. PU.1 and Spi-B are E26transformation–specific transcription factors that are critical for B cell differentiation. To
determine whether PU.1 and Spi-B are required for B cell development in the bone
marrow, Spi1 (encoding PU.1) was conditionally deleted in B cells by Cre recombinase
under control of the Mb1 gene in Spib (encoding Spi-B)–deficient mice. Combined
deletion of Spi1 and Spib resulted in a lack of mature B cells in the spleen and a block in
B cell development in the bone marrow at the Small Pre-B cell stage. To determine target
genes of PU.1 that could explain this block, we applied a gain-of-function approach using
a PU.1/Spi-B–deficient Pro-B cell line in which PU.1 can be induced by doxycycline.
PU.1-induced genes were identified by integration of chromatin immunoprecipitation–
sequencing and RNA-sequencing data. We found that PU.1 interacted with multiple sites
in the Igκ locus, including Vκ promoters and regions located downstream of Vκ second
exons. Induction of PU.1 induced Igκ transcription and rearrangement. Upregulation
of Igκ transcription was impaired in Small Pre-B cells from PU.1/Spi-B–deficient bone
marrow. These studies reveal an important role for PU.1 in the regulation of Igκ
transcription and rearrangement and a requirement for PU.1 and Spi-B in B cell
development.

2

Text and figures within this section have been adapted from the previously published manuscript:

Batista, C. R., Li, S. K. H., Xu, L. S., Solomon, L. A., & DeKoter, R. P. (2017). PU.1 Regulates Ig Light
Chain Transcription and Rearrangement in Pre-B Cells during B Cell Development. The Journal of
Immunology, 198(4), 1565–1574. http://doi.org/10.4049/jimmunol.1601709
CopyrightÓ The American Association of Immunologists, Inc. (AAI).
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2.1

Introduction
B cell development involves ordered rearrangement of Ig loci encoding H and L

chain proteins that assemble into Abs capable of recognizing specific Ags. Stages of B
cell development can be resolved using cell surface marker expression, as well as Ig gene
rearrangement (Hardy, 1991; L. Lu, Smithson, Kincade, & Osmond, 1998; Osmond,
Rolink, & Melchers, 1998). Progenitor B (Pro-B; also known as Pre-BI) cells are
generated from lymphoid progenitors and initiate D-J segment rearrangement of Igh H
chain alleles. Rearrangement of Igh alleles is completed by V-DJ rearrangement to encode
H chains that can pair with surrogate L chain proteins and be deposited on the cell surface
as a Pre-BCR. Pre-BCR signaling promotes proliferation of Large Pre-B cells (also
known as Pre-BII cells). Cessation of proliferation induces re-expression of the RAG
proteins RAG1 and RAG2, whose interaction is wide spread throughout the Ig loci at
recombination signal sequences (RSSs) (Teng et al., 2015). Finally, successful pairing of
Ig kappa or lambda chain proteins with IgH proteins results in expression of a BCR in
immature B cells (Corfe & Paige, 2009). Immature B cells emigrate from the bone
marrow (BM) to the spleen to complete their maturation (Allman et al., 2001).
The mouse Igk locus contains 101 functional Vk genes, 60 Vk pseudogenes, 4
functional Jk genes, 1 J pseudogene, and 1 Ck gene. The Igk locus comprises > 3 MB of
genomic sequence (de Almeida, Hendriks, & Stadhouders, 2015). Recombination occurs
in a developmental stage–specific order that is thought to be regulated at the level of
chromatin accessibility to RAG proteins (Aoki-Ota, Torkamani, Ota, Schork, &
Nemazee, 2012; Yancopoulos & Alt, 1985). Accessibility is likely controlled at the level
of transcription, as supported by two lines of evidence. First, deletions of enhancers
within the Igk locus impair transcription and Ig recombination (Inlay et al., 2002;
Sleckman, Gorman, & Alt, 1996). Second, deletion of genes encoding histone modifying
enzymes or transcription factors reduce transcription and Ig recombination (de Almeida
et al., 2015). Thus, Ig locus accessibility is regulated by transcription factor recruitment
of the transcriptional machinery to regulatory regions within the Igk locus.
B cell development is coordinated by the expression of a number of cell type– and
developmental stage–specific transcription factors, including E2A, EBF, Pax5, Ikaros,
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PU.1, and Spi-B (Swee Heng Milon Pang, Carotta, & Nutt, 2014). PU.1 (encoded by
Spi1) and Spi-B (encoded by Spib) are highly related transcription factors of the E26
transformation–specific (ETS) family (Solomon et al., 2015). Several lines of evidence
suggest that PU.1 might play an important role in the control of Igk transcription. Igk V
region promoters, as well as the intronic and 39 enhancers in the Igk locus, contain
predicted binding sites for PU.1 (Brekke & Garrard, 2004; Pongubala & Atchison, 1991;
Schwarzenbach, Newell, & Matthias, 1995). Chromatin immunoprecipitation–
sequencing (ChIP-seq) analysis in Pro-B cells reveals that PU.1 binding is widespread
throughout the Igk locus (de Almeida et al., 2015; Schwickert et al., 2014). However,
there has not been a clear demonstration of a role for PU.1 in Ig transcription,
accessibility, or rearrangement in vivo. The ability of Spi-B to complement PU.1 function
may have impeded a clear demonstration of PU.1 as a regulator of Igk gene transcription
(Solomon et al., 2015; L. S. Xu et al., 2012). We previously generated mice that delete
Spi1 encoding PU.1 under control of CD19-Cre on Spib-/- background of IgM (L. S. Xu
et al., 2012). These mice had impaired development of follicular B cells and perturbation
of BM B cell development, demonstrating a complementary role for PU.1 and Spi-B in
B cell development and function (Christie et al., 2015; Sokalski et al., 2011). However,
CD19-Cre does not delete alleles efficiently in BM (Hobeika et al., 2006), precluding an
examination of PU.1 and Spi-B function in early B cell development.
We hypothesized that deletion of Spi1 and Spib during early B cell development
would reveal a role for PU.1 and/ or Spi-B in the transcription and rearrangement of Ig
genes. To test our hypothesis, Mb1+/CreSpi1lox/loxSpib-/-(Mb1-CreDPB) mice were
generated by crossing Spi1lox/loxSpib-/- mice to Mb1+/Cre mice. Mb1-Cre deletes alleles
with high efficiency in BM (Hobeika et al., 2006), resulting in a Spib-deficient mouse
that is expected to have high frequency of Spi1 deletion during early B cell development.
Analysis of adult mice showed that deletion of Spi1 and Spib in Mb1-CreDPB mice
resulted in the absence of IgM+ B cells in the spleen. In BM, there was a specific block
in B cell development at the Small Pre-B cell to immature B cell transition that is marked
by successful rearrangement of Ig L chain genes. To determine target genes of PU.1 that
could explain this block, we applied a gain-of-function approach using a PU.1/Spi-B–
deficient Pro-B cell line in which PU.1 can be induced by doxycycline. PU.1-regulated
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genes were identified by integration of ChIP-seq and RNA-sequencing (RNA-seq) data.
PU.1 interacted with 23,647 sites located near transcription start sites (TSSs) of genes
involved in immune system development. Interestingly, we observed PU.1 interaction
with multiple sites in Vk gene promoters, as well as sites downstream of Vk second exons
located near RSSs. Induction of PU.1 resulted in increased transcription of Igk V genes
and Igk rearrangement. Finally, we found that upregulation of Igk transcription was
impaired in PU.1 and Spi-B–deficient BM Pre-B cells. These studies reveal an important
role for PU.1 in Igk transcription and rearrangement and a requirement for PU.1 and SpiB in B cell development.

2.2

Results

2.2.1 Deletion of Genes Encoding PU.1 and Spi-B Impairs B Cell
Development at the Pre-B to Immature B Cell Transition
It was shown that mice lacking PU.1 or Spi-B in the B cell lineage have relatively
normal B cell development and mild impairment of B cell function (S. H. M. Pang et al.,
2016; Polli et al., 2005; Ye et al., 2005). However, mice lacking PU.1 and Spi-B in the B
cell lineage (Cd19+/Cre Spi1lox/lox Spib-/- mice) have reduced numbers of B cells, suggesting
that these factors are important during development (Christie et al., 2015; Sokalski et al.,
2011). We sought to determine whether efficient deletion of PU.1 and Spi-B in the early
stages of B cell development in BM would result in a block at a specific stage. Mice that
delete Spi1 under control of the Cd79a (Mb-1) gene, which deletes alleles efficiently in
BM (Hobeika et al., 2006), were bred to Spib-/- mice to generate Mb1-CreDPB mice
(lacking PU.1 and Spi-B), Mb1-CreDP mice (lacking PU.1), and DB mice (lacking SpiB). To assess B cell development, the frequency of mature B cells in the spleen of 6–10
weeks old mice was determined. Mb1-CreDPB mice had few B220+ IgM+ B cells in the
spleen compared with WT or DB mice (Fig. 2.1). Therefore, PU.1 and Spi-B are required
to generate splenic B cells.

45

Figure 2. 1. Absence of PU.1 and Spi-B During B Cell Development Severely Impairs
B Cell Maturation.
(A) Flow cytometric analysis of B220 and IgM cell surface expression of spleen cells
prepared from WT (left panel), DB (center panel), and Mb1-CreDPB (right panel) mice.
(B) Percentage of B220+ IgM+ cells in WT, DB, and Mb1-CreDPB mice (n = 7). Data
are mean ± SEM. ***p < 0.001.
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To determine the stage at which the block of B cell development was occurring,
the frequencies of developing B cells in BM of 6–10-wk-old Mb1-CreDPB mice were
measured using flow cytometry according to the cell surface marker scheme described by
Hardy et al. (Hardy, Carmack, Shinton, Kemp, & Hayakawa, 1991). There were no
significant differences in the frequencies of B220+ cells among the groups (Fig. 2.2 A,
B). However, immature BM B cells (B220+CD43+) were increased in frequency and
mature BM B cells (B220+ CD43-) were decreased in frequency in Mb1-CreDPB mouse
BM compared with Mb1-CreDP, DB, and WT mouse BM (Fig. 2.2 C–E). As a proportion
of total B220+ cells, there were reduced frequencies of cells at the pre–pro B cell stage,
or Fraction A, in Mb1-CreDPB, Mb1-CreDP, and DB mice compared with WT mice (Fig.
2.2 F, G).
There were increased frequencies of Fraction B (Pro-B/Pre-BI) cells and Fraction
C (Pre-B, Large Pre-B/ Pre-BII) cells in Mb1-CreDPB mouse BM compared with controls
(Fig. 2.2 F, G). Mb1-CreDPB mice had double the frequency of Fraction C BM cells
compared with controls (Fig. 2.2 F, G). None of the groups analyzed showed significant
differences in the frequencies of Fraction D (Small Pre-B) cells. However, Fraction E
(immature B cells) and Fraction F (mature recirculating B cells) were nearly absent in
Mb1-CreDPB BM. Strikingly, there were no B cells expressing high levels of surface Ig
in 6–10-wk-old Mb1-CreDPB mice (Fig. 2.2F, G). These results demonstrate a critical
requirement for PU.1 and Spi-B in the transition from Small Pre- B cells to immature B
cells.
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Figure 2. 2. Deletion of PU.1 And Spi-B Blocks B Cell Development in the BM at the
Pre-B Cell Transition.
(A) Representative graph showing the percentage of B220+ cells in WT, Mb1-CreDP, DB,
and Mb1-CreDPB mice. (B) Percentage of B220+ cells in BM of WT, Mb1-CreDP, DB,
and Mb1-CreDPB mice. (C) Representative flow cytometric analysis showing the
percentage of B220+ CD43+ and B220+ CD43+ cells in WT (left panel) and Mb1-CreDPB
(right panel) mice. (D) Percentage of B220+ CD43+ cells in BM of WT, Mb1-CreDP, DB,
and Mb1-CreDPB mice. (E) Percentage of B220+ CD43+ cells in BM of WT, Mb1-CreDP,
DB, and Mb1-CreDPB mice. (F) Representative flow cytometric analysis according to the
Hardy scheme representing the frequency of developing B cells in Fractions A–C in WT,
Mb1-CreDP, DB, and Mb1-CreDPB mice (gated on B220+ CD43+ population) (upper
panels). Flow cytometric analysis according to the Hardy scheme representing the
frequency of developing B cells in Fractions D–F in WT, Mb1-CreDP, DB, and Mb1CreDPB mice (gated on B220+ CD432 population) (lower panels). (G) Percentage of
B220+ cells in BM of WT, Mb1-CreDP, DB, and Mb1-CreDPB mice in Fractions (A–F).
WT, n = 10; Mb1-CreDP, n =8; DB, n = 9; and Mb1-CreDPB, n = 12. Data are mean ±
SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
.
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2.2.2 Analysis of PU.1 Target Genes in the Pro-B Cell Line i660BM
To identify target genes of PU.1 that could explain the developmental block in
Mb1-CreDPB mouse BM, we applied a gain-of-function approach using a PU.1-inducible
Pro-B cell line (Fig. 2.3 A). The 660BM cell line is fully deleted for Spi1 and Spib, has a
nonproductive rearrangement of the Igh locus, and is germline for Igk locus
rearrangement. This cell line was implemented through the BM isolation from a germline
knockout for Spib mouse (660), which Spi1 gene was deleted by Cre recombinase under
control of the Cd19 gene. After BM isolation, 660BM cells were kept in IL-7-conditioned
media and have shown the ability to proliferate indefinitely in the presence of IL-7
(Christie et al., 2015). 660BM cell line was infected with a two-vector inducible system
in which PU.1 is inducible using 70 ng/ml doxycycline (Christie et al., 2015), originating
the i660BM cell line. To define sites of PU.1 interaction, anti-PU.1 ChIP was performed
on chromatin prepared from i660BM cells induced with (+DOX) or without (-DOX) 70
ng/ml doxycycline for 24 h. Illumina sequencing was performed on two biological
replicates of PU.1-induced chromatin, as well as input chromatin. An average of 70
million 100-bp single-end reads were obtained. Reads were aligned to the mouse genome
(mm10), and data were analyzed using the Galaxy suite of software tools. PU.1 was found
to be associated with 49,385 unique genomic regions. The top interaction motif recovered
for all PU.1-associated regions was the ETS motif containing the core A/5’-GGAA-3’
sequence (Fig. 2.3 B). PU.1 was found to associate primarily with distal intergenic regions
and gene bodies, similar to what was reported previously for PU.1 in splenic B cells (Fig.
2.3 C) (Heinz et al., 2010). Seventeen percent of PU.1-interaction sites were at annotated
gene promoters, and 23,647 peaks were located within 15 kb of annotated TSSs (Fig. 2.3
C, D).
Next, RNA-seq analysis was performed on three biological replicates of RNA
prepared from i660BM cells induced or not with 70 ng/ml doxycycline for 48 h. An
average of 60 million 100-bp paired-end reads were obtained per sample. RNA-seq reads
were aligned to the mouse genome (mm10) using TopHat, and differential gene
expression was determined using Cufflinks suite. Genes presenting a log2-fold change in
expression > 0.5 were considered in our analysis. Using these criteria, transcript levels of
811 genes were significantly increased upon PU.1 induction, and transcript levels of 531
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genes were significantly decreased upon PU.1 induction (Supplemental Table II is
available on the online version of this manuscript). To identify PU.1-regulated genes, the
genomic region that interacts with PU.1 was associated with differentially expressed
transcripts. A total of 793 of 811 upregulated genes and 521 of 531 downregulated genes
were associated with PU.1 binding sites located within 15 kb of the TSS, suggesting that
these genes were regulated directly by PU.1 (Fig. 2.3 E). As shown in Fig. 3F, 670 PU.1associated genes were upregulated and 465 PU.1-associated genes were downregulated
with fold changes in expression, log2 (1.5). However, 141 genes were upregulated log2
(1.5)-fold, of which 12 were upregulated log2 (5)-fold. Sixty-six genes were
downregulated log2 (1.5)-fold, of which five were downregulated log2 (3)-fold (Fig. 2.3
F). In summary, 793 upregulated gene transcripts and 521 downregulated gene transcripts
were associated with PU.1 peaks and, therefore, were considered direct targets of PU.1
regulation.
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Figure 2. 3. Identification of PU.1-Regulated Genes in i660BM Pro-B cells.
(A) Flow chart illustrating the strategy used to identify PU.1- regulated genes. RNA-seq
of i660BM cells in the presence (+DOX) or absence (-DOX) of doxycycline was
integrated with PU.1 ChIP- seq data sets to determine PU.1-regulated genes.
Differentially expressed genes in the RNA-seq were categorized by the presence or
absence of PU.1 binding within 15 kb of the TSS. (B) Motif enrichment analysis of PU.1
ChIP-seq data shows the ETS binding motif as the primary motif of PU.1 binding. (C)
Pie chart representing the enrichment of PU.1 binding across genomic regions based on
PU.1 ChIP-seq analysis. (D) Clustering of PU.1 ChIP-seq data demonstrates PU.1enriched regions at the TSS of mouse RefSeq genes. (E) Defining PU.1-regulated genes.
Venn diagrams illustrate the number of TSS-associated PU.1 peaks associated with
upregulated (left panel; green circle) and downregulated (right panel; red circle) genes
from the RNA-seq experiment. (F) Distribution of PU.1-regulated genes according to
RNA-seq fold change (log2).
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2.2.3 Gene Ontology Analysis of PU.1 Targets
Upregulated and downregulated genes associated with PU.1 binding in i660BM
cells were explored further using gene ontology analysis. Protein-classification analysis
showed that 11% of PU.1- upregulated or -downregulated genes encoded proteins related
to nucleic acid binding, whereas 7% of upregulated or downregulated genes encoded
transcription factors (Fig. 2.4 A). PU.1-regulated genes encoded cell signaling molecules,
cell receptors, and cellular transporters, among others, illustrating a broad role for PU.1
in regulating diverse cellular processes (Fig. 2.4 A, B). Gene ontology analysis using
DAVID showed that upregulated genes were classified into biological processes
including immune response, cell activation, and lymphocyte activation (Fig. 2.4 C).
Downregulated genes were classified into biological pathways including
nucleosome assembly, chromatin assembly, and nucleosome organization (Fig. 2.4 C).
These genes included a number of genes previously shown to be directly regulated by
PU.1, such as Blnk (38), Il7r (39), and E2f1 (40) (Fig. 2.4 B). Interestingly, Rag1/Rag2
was the fifth most upregulated gene and was associated with an upstream peak in PU.1
interaction (Fig. 2.4 D). Id2, an inhibitor of E2A transcription factor activity, was a
downregulated gene that was associated with a peak in PU.1 interaction (Fig. 2.4 E). RTqPCR analysis confirmed upregulation of Rag1, Rag2, and Spi1 transcript levels, as well
as downregulation of Id2 mRNA transcript levels (Fig. 2.4 F). These results suggest that
PU.1 directly regulates genes involved in BCR signaling, as well as Ig recombination
and/or accessibility.
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Figure 2. 4. Characterization of PU.1-Regulated Genes.
(A) Gene ontology data analysis showing the PANTHER protein classification of PU.1regulated genes (left panel, upregulated; right panel, downregulated). (B) Examples of
PU.1-upregulated (↑) and downregulated (↓) genes according to the protein classification
ontology analysis. Numbers indicate log2 fold change. (C) Gene ontology analysis by
DAVID identifying the biological processes related to PU.1-regulated genes (left panel,
upregulated; right panel, downregulated). (D) UCSC genome browser tracks of PU.1
ChIP and RNA-seq experiments showing Rag2 and Rag1 genes. (E) UCSC genome
browser tracks of PU.1 ChIP and RNA-seq experiments showing Id2 gene. (F)
Confirmation of changes in gene expression. RT-qPCR analysis for the indicated genes
was performed on four biological replicates of RNA prepared from uninduced (-DOX) or
70 ng/ml doxycycline-induced (+DOX) i660BM cells cultured in 2.5% IL-7–conditioned
medium. *p < 0.05, ***p < 0.001, ****p < 0.0001.

56

A

B
PU.1 peaks
on up genes
5.1%

8.2%

7.7%

32.4%

5.9%

7.3%

4.4%

9.5%

7.1% 8.1%

Immune Protein

Enzyme Modulator

Transporter

Receptor

Signaling Molecule

Others

Transcription Factor

Nucleic Acid Binding

Hydrolase

Transferase

C

Rasa4 (5.55)
Blnk (3.78)
Cxcl10 (2.1)
Icam1 (1.35)
Il5ra (1.30)
Bcl2l1 (0.97)
Cd274 (0.69)
Il16 (0.64)
Lgals9 (0.54)
Il7 (0.53)

11%

7.5% 8.4%

Nucleic Acid Binding

Id1 (-3.18)
Id2 (-2.08)
Ikzf4 (-1.38)
Ell3 (-1.0)
Fos (-0.9)
Gfi1 (-0.8)
Myc (-0.76)
Ets1 (-0.5)

Foxo1 (0.58)
Runx1 (0.53)
Ikzf3 (0.53)

Signaling Molecules

26.2%

7.1%

10.6%

3.9%

10.8%

7.6%

11.2%

Transcription factors
Pou6f1 (7.02)
Spi1 (2.7)
Bcl6 (1.8)
Rb1 (0.97)
E2f1 (0.78)
Erg (0.75)
Myb (0.70)
Nfkb2 (0.61)

PU.1 peaks
on down genes

Il7r (1.71)
Lgr5 (1.43)
Il10ra (1.06)
Adora2a (0.98)
Il2ra (0.69)
Cxcr4 (0.63)
Csf2rb (0.59)

Crisp3 (-2.19)
Colq (-0.88)

chr2:101,623,675-101,649,955 (mm10)

PU.1 ChIP

10kb

Rag2

-dox

+dox

Rag1

*

Fold Expression

1
100

Hfe (1.04)
Vpreb3 (0.91)
Vpreb1 (0.8)
Oas1b (0.64)
Cd2 (0.53)

p value (-log10)

Fold Expression

1
100

Ccr2 (-2.88)
Shroom3 (-2.75)
Ccr5 (-2.42)
Ccr4 (-1.97)
Cxcr5 (-1.74)
Ifnlr1 (-1.39)
Ffar1 (-1.36)
Il4ra (-1.35)
Il21r (-0.65)
Fas (-0.58)
Cr2 (-0.54)
Il2rg (-0.53)

BP_PU.1 peaks on
down genes

p value (-log10)
220

Hist1h2bm (-0.56)
Nanos1 (-0.54)
Nlrp10 (-0.52)
Hist1h2bc (-0.51)
Rpl10a (-0.50)

Immune Protein

Receptor

Cd22 (-1.57)
Lcp2 (-1.48)
Tgfb3 (-1.27)
Bcl2 (-1.06)
Tnf (-0.79)
Socs3 (-0.60)
Socs2 (-0.56)

BP_PU.1 peaks on
up genes

D

Hist1h2ab (-1.15)
Hist1h1e (-1.04)
Hist1h2ak (-1.02)
Hist1h2bk (-0.73)
Hist1h2bb (-0.73)
Hist1h2bh (-0.64)
Papolg (-0.57)

Rag1 (6.96)
Dntt (1.6)
Syk (1.58)
Hmx2 (0.87)
Polm (0.72)
Lig4 (0.6)

*

1

Rag2

DOX- DOX+

Rag1

Id2

1kb

1
10,000

1

-dox
+dox

Btk

****

DOX- DOX+

Id2

57

*

DOX- DOX+

Spi1
Fold Expression

PU.1 ChIP

1
10,000

DOX- DOX+

chr12:25,093,799-25,096,092 (mm10)

Fold Expression

300

Fold Expression

E

***

DOX- DOX+

2.2.4 Regulation of Igk Transcription and Recombination by PU.1
Upregulation of Rag mRNA transcripts and downregulation of Id2 mRNA
transcripts suggested that PU.1 may be involved in the regulation of Igk rearrangement
during B cell development. Igk V-J rearrangement is preceded by increased transcription
of V region genes, as well as of sterile transcripts initiating in regulatory regions (Schlissel
& Stanhope-Baker, 1997; Yancopoulos & Alt, 1985). Analysis of ChIP-seq data
identified 179 peaks in PU.1 interaction within the 3-Mb Igk locus, of which 60 were
located in GENCODE-annotated Igk genes (Fig. 2.5 A). Analysis of RNA-seq data
revealed widespread changes in Igk V region mRNA transcript levels upon PU.1
induction (Fig. 2.5 B). For 166 annotated Igk genes, 69 were unchanged, 42 were
downregulated, and 55 were upregulated in the RNA-seq analysis (Fig. 2.5 B,
Supplemental Table III available in the online version of this manuscript). Thirty peaks
in PU.1 interaction were associated with upregulated Igk V transcripts, and 10 peaks in
PU.1 interaction were associated with downregulated Igk V transcripts (Fig. 2.5 A). Igk
V genes that were upregulated upon PU.1 induction included Igkv1-135, Igkv10-96,
Igkv4-57, Igkv6-13, and Igkv4-73 (Fig. 2.5 B). Interestingly, there were two distinct
patterns of PU.1 interaction with Ig V genes. PU.1 interacted with the promoters of 11 V
genes, with a region downstream of the second exon of 26 V genes, and with both the
promoter and a region downstream of the second exon of 14 genes (Fig. 2.5 C,
Supplemental Table IV, online version of this manuscript). For the Igkv4 family, PU.1
interacted with 11 sites downstream of the second exon and only one site in a promoter.
For the IgkV6 family, PU.1 interacted with both the promoter and a site downstream of
the second exon for six members (Fig. 2.5 C, D). A total of 32 of 40 PU.1 sites
downstream of V region second exons were located an average of 91 bp from the RSS
heptamer sequence 5’-CACAGTG-3’. MEME analysis of the 32 genomic regions
associated with PU.1 binding sites located downstream of V region second exons revealed
a 12-bp RSS as the most frequently discovered motif (Fig. 2.5 E). Taken together, these
results indicate that PU.1 interacts with a number of sites downstream of Igk V region
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second exons that are located close to RSSs. This suggests that PU.1 might be involved
in the regulation of chromatin accessibility near RSSs.
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Figure 2. 5. PU.1 Binds to the Igk Locus and Induces Transcription of Variable Genes.
(A) Venn diagrams showing the number of PU.1 peaks located on upregulated and
downregulated Igk V genes. (B) Heat map showing the differential expression of Igk V
genes with (+DOX) or without (-DOX) doxycycline using the mouse genome annotation
available on GENCODE. (C) Distribution of PU.1 peaks within the Igk V locus. (D)
Distribution of PU.1 peaks separated by Igk V family. (E) MEME motif analysis of
sequences containing PU.1 peaks downstream of Igk V gene second exons show RSS as
a top enriched motif.
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2.2.5 PU.1 Induction Induces Igk V-J Rearrangement
Because PU.1 interacts with Igk V region genes, induces Igk V region
transcription, and induces Rag transcription, we hypothesized that PU.1 induction in
i660BM cells coupled with reduced IL-7 concentration might be sufficient to induce Igk
V-J rearrangement in i660BM cells. To confirm this, Igk V-J rearrangement was
measured using DNA prepared from i660BM cells in which PU.1 was induced with
doxycycline in the presence of a high or low concentration of IL-7. DNA prepared from
WT spleen cells was used as a control. Low IL-7 concentration or PU.1 induction resulted
in low levels of Igk V-J rearrangement in i660BM cells. Igk V-J rearrangement was
robustly detected in i660BM cells in which PU.1 was induced with a low concentration
of IL-7 (Fig. 2.6 D, left side). In the parent 660BM cells that did not express PU.1, reduced
IL-7 concentration was not sufficient to induce Igk V-J rearrangement (Fig. 6D, right
side). We conclude that induction of PU.1 expression, coupled with reduced IL-7
concentration, is sufficient to induce Igk V-J rearrangement in a cultured Pro-B cell line.
Quantitative PCR analysis confirmed that each of these Igk V genes was inducible
by PU.1, and reduced IL-7 concentration resulted in increased induction of transcription
by PU.1 (Fig. 2.6 A). Each of these Igk V genes was associated with at least one peak in
PU.1 interaction (Fig. 2.6 B). PU.1 also was shown to interact with the 2-4 and 3-1
enhancers in the Igl locus (Eisenbeis, Singh, & Storb, 1993). Interestingly, induction of
PU.1 increased Igl1 mRNA transcript levels (Fig. 2.6 C). These results suggest that PU.1
directly regulates Igk and Igl V region transcription in i660BM cells.
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Figure 2.6. Induction of PU.1 in i660BM Pro-B cells Induces Transcription and
Rearrangement of the Igk Locus.
(A) RT-qPCR for detection of Igkv1-135, Igkv10-96, Igkv4-57, Igkv6-13, and Igkv4-73
transcripts with (+DOX) or without (-DOX) doxycycline in conditions of high and low
IL-7 (5% and 2.5%, respectively). UCSC genome tracks (left panels) show the PU.1
binding peak from PU.1 ChIP-seq data and the transcription tracks from the RNA-seq
experiment in conditions without (-DOX) and with (+DOX) doxycycline. (B) UCSC
genome browser tracks of PU.1 ChIP sequencing and RNA-sequencing. Tracks show
PU.1 binding to Igkv1-135, Igkv10-96, Igkv4-57, Igkv6-13, and Igkv4-73 and increased
expression (C) PU.1 induces Igl germline transcription. RT-qPCR analysis of the Igl1
mRNA transcript was performed on four biological replicates of RNA prepared from
uninduced (-DOX) or 70 ng/ml doxycycline-induced (+DOX) i660BM cells cultured in
2.5% IL-7 conditioned medium. D) PCR for detection of Igk-chain rearrangement (IgvkIgJk5) in i660BM and 660BM cells without doxycycline (-DOX) and with doxycycline
(+DOX) induction and various levels of IL-7.
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2.2.6 Reduced Igk Transcription in BM Pre-B Cells from Mb1-CreDPB
Mice
Igk V gene transcription is upregulated during theLarge Pre-B (Fraction C) to
Small Pre-B (Fraction D) transition (Painter, Davis, Hardy, Mathis, & Benoist, 2011).
BM B cell development was blocked at the Small Pre-B cell stage in the absence of PU.1
and Spi-B (Fig. 1). Because induction of PU.1 resulted in increased Igk V region
transcript levels and Igk V-J recombination, we hypothesized that Mb1-CreDPB Pre-B
cells might have a reduced ability to activate Igk V-J transcription. To test this, Fraction
C and Fraction D Pre-B cells were enriched from the BM of Mb1-CreDPB mice, or DB
mice as controls, using cell sorting; the gating strategy is shown in Fig. 2.2 F. Fraction E
cells were not enriched, because this Fraction was absented in Mb1-CreDPB mice (Fig.
2.2 G).
Quantitative PCR was used to determine changes in transcript levels of Igk V
genes with which PU.1 interacted. We found that, in BM cells from DB mice, Igk V gene
transcription was upregulated during the Fraction C to Fraction D transition for Igkv1135, Igkv12-98, Igkv12-44, Igkv3-5, and the sterile transcript Glk-1 (Fig. 2.7 A–F). In
contrast, transcript levels for Btk and the control gene b-actin did not change (Fig. 2.7 G,
H). In BM cells enriched from Mb1-CreDPB mice, mRNA transcript levels for Igkv1135, Igkv12-98, Igkv12-44, Igkv3-5, and Glk-1 failed to increase during the Fraction C
to Fraction D transition (Fig. 2.7 B–F). Transcript levels for Spi1 and its target gene (Btk)
decreased, consistent with deletion of Spi1 at this transition, whereas the control gene bactin did not change from Fraction C to Fraction D (Fig. 2.7 G–I). These data demonstrate
that PU.1 and Spi-B are important for inducing transcription of certain Igk V genes during
B cell development in the BM and suggest that the absence of PU.1 and Spi-B might lead
to reduced Igk V region accessibility and V-J recombination.
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Figure 2.7. Absence of PU.1 and Spi-B in Vivo Results in Reduced Levels of Igk
Transcripts in Small Pre-B Cells.
(A) Schematic diagram of the mouse Igk locus showing the variable (V) region, the
joining and constant regions (C-V regions), and the gene segments assessed in this study
by RT-qPCR. Variable gene segments are highlighted, and the Glk-1 (ko) transcript is
also indicated. (B–E) RT-qPCR showing the fold induction of the Igkv1-135, Igkv12-98,
Igkv12-44, and Igkv3-5 genes in developing B cells from Fraction C (Large Pre-B cells)
and Fraction D (Small Pre-B cells) of DB and Mb1-CreDPB mouse BM. (F) RT-qPCR
showing the fold induction of the Glk-1 mRNA transcript in developing B cells from
Fraction C (Large Pre-B cells) and Fraction D (Small Pre-B cells) of DB and Mb1CreDPB mouse BM. (G–I) RT-qPCR showing the fold induction of b-actin, Btk, and Spi1
mRNA transcripts in developing B cells from Fraction C (Large Pre-B cells) and Fraction
D (Small Pre-B cells) of DB and Mb1-CreDPB mouse BM. *p < 0.05, **p < 0.01, ***p
< 0.001, ****p < 0.0001.
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Discussion
In this study, we showed that B cell development is blocked in mice that delete

the Spi1 gene encoding PU.1 under control of the Mb1 locus, which are also germline
knockout for Spib (Mb1-CreDPB mice). Adult Mb1-CreDPB mice did not have splenic B
cells, and few surface IgM+ B cells were present in BM, suggesting a block in B cell
development starting at the Pre-B cell stage. Identifying target genes of PU.1 and/or SpiB might explain this block in B cell development; therefore, a Spi1/Spib-deleted IL-7–
dependent Pro-B cell line was used in which PU.1 expression can be induced using
doxycycline (i660BM cells). RNA-seq and anti-PU.1 ChIP-seq experiments were
performed to determine the genome-wide target genes of PU.1 in this model. These
experiments confirmed a number of previously identified PU.1 target genes involved in
the Pro-B to Pre-B cell developmental transition. Unexpectedly, the Rag locus was also
found to be a direct target of PU.1 induction. Closer examination revealed that PU.1
interacted with 179 sites within the Igk locus, of which 60 sites were located within V
genes, including at V gene promoters and near RSSs. An increase in PU.1 expression,
combined with reduced IL-7 concentration, induced Igk rearrangement. Finally, we found
that Igk V region mRNA transcript levels were not increased at the Pro-B to Pre-B cell
transition in Mb1-CreDPB mice. These results show that PU.1 directly regulates Igk locus
transcription and suggest that PU.1 is an important regulator of Igk locus accessibility
during B cell development.
Comparison of BM B cell development in Mb1-CreDPB mice with that in control
mice revealed a relative increase in the frequency of Pre-BII/Large Pre-B cells (Fraction
C), no difference in the frequency of Small Pre-B cells (Fraction D), and a near absence
of immature sIgM+ B cells (Fraction E). These results are most consistent with a block in
B cell development at the stage when Ig L chain recombination is taking place in Small
Pre-B cells. Previous analysis of CD19-CreDPB mice, which did not delete alleles
efficiently in BM, showed a relative increase in immature B cell frequencies in BM but a
decrease in mature recirculating B cells (Fraction F) and in the frequency of splenic
follicular B cells. The differences between these two models suggest that PU.1 and SpiB play important roles in B cell development at late, as well as early, stages.
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B cell–specific deletion of the gene encoding PU.1 in mice (Polli et al., 2005; Ye,
Ermakova, & Graf, 2005) or deletion of the gene encoding Spi-B in mice (Su et al., 1997)
resulted in relatively mild defects in B cell development. Similarly, deletion of the Irf4 or
Irf8 gene resulted in mild B cell developmental defects

(Holtschke et al., 1996;

Mittrucker, 1997). Combined deletion of Spi1 and Irf8 resulted in mild impairment of B
cell development, whereas combined deletion of Spi1 and Irf4 resulted in impaired B cell
development at the Pre-B cell stage (S. H. M. Pang et al., 2016). Strikingly, combined
deletion of Irf4 and Irf8 resulted in a block in B cell development at the Pre-B cell stage
(R. Lu, Medina, Lancki, & Singh, 2003). In this study, we showed that combined deletion
of Spi1 and Spib results in a block in B cell development at the Pre-B cell stage.
Collectively, these studies reveal a critically important PU.1/Spi-B/IRF4/IRF8 regulatory
axis for Pre-B cell development. PU.1 and Spi-B interact interchangeably with IRF4 or
IRF8 to regulate genes containing ETS-IRF composite elements (EICEs) (Singh,
Glasmacher, Chang, & Vander Lugt, 2013). Recently, it was shown that ∼50% of PU.1
binding sites in Pro-B cells are at EICEs, suggesting that this regulatory element may
control a large number of genes in developing B cells (S. H. M. Pang et al., 2016). These
studies collectively suggest that genes important for early B cell development require
activation through EICEs to promote their expression. More work is necessary to identify
key EICE-regulated target genes.
PU.1 was implicated in the regulation of Ig transcription in numerous studies. In
1991, PU.1 was recognized to interact with the Igk 3’ enhancer cooperatively with IRF4
(Mittrucker, 1997; Pongubala & Atchison, 1991). Transgenic studies implicated the PU.1
binding site in the Igk 3’ enhancer in the regulation of the developmental stage specificity
of V-J joining (Hayashi et al., 1997). In 1995, PU.1 was identified as an NF capable of
interacting with pyrimidine-rich sequences in the Vk19 promoter (Schwarzenbach,
Newell, & Matthias, 1995). PU.1 binding sites were predicted in numerous V region
promoters of the Igk locus (Brekke & Garrard, 2004). Previous studies showed that PU.1
interacts with numerous sites in the Igk locus in the B cell lineage. In mature splenic B
cells, PU.1 was shown to interact with 45 sites in the 3-Mb Igk locus (Heinz et al., 2010).
In Pro-B cells, PU.1 was shown to interact with 181 sites in the Igk locus (Schwickert et
al., 2014). This study closely agrees with our result of 179 total PU.1 binding sites in the
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Igk locus, and 74 of these sites were in common, with 35 of these sites in common in all
three studies. Taken together, these studies correspond with our identification of PU.1
binding sites in the Igk locus.
The 3’ enhancer of the Igk locus is critical for the cell type and developmental
stage specificity of V-J rearrangement (Gorman et al., 1996; Hayashi et al., 1997; Inlay
et al., 2002; Mandal et al., 2011; Shaffer, Peng, & Schlissel, 1997). STAT5 binding
induced by IL-7 signaling is a critically important repressor of Igk transcription to prevent
accessibility and rearrangement during proliferation of Large Pre-B/Pre-BII cells
(Mandal et al., 2011). PU.1 can compete with STAT5 for interaction with the Igk 3’
enhancer to regulate Igk transcription (Hodawadekar, Park, Farrar, & Atchison, 2012).
Consistent with these studies, our results showed that PU.1 induced Igk transcription and
rearrangement more efficiently when IL-7 concentration was reduced (Fig. 5). Our results
are consistent with PU.1 being an important factor for inducing Igk transcription and
accessibility when developing Pre-B cells migrate away from high IL-7 concentrations
(Clark et al., 2014). Igk V region transcription is closely associated with accessibility of
the recombinase apparatus and initiation of Igk V-J recombination (Schlissel & StanhopeBaker, 1997; Yancopoulos & Alt, 1985). The results presented in Fig. 6 demonstrate that
Igk V region transcripts are not appropriately upregulated in the absence of PU.1 and SpiB. This suggest that PU.1 and Spi-B are important regulators of Igk V region
transcription, accessibility, and rearrangement. The absence of IgM+ B cells in Mb1CreDPB mice suggests that Igl transcription may also be impaired in the absence of PU.1
and Spi-B. Consistent with this idea, induction of PU.1 activated Igl1 transcription in
i660BM cells (Fig. 5D). We previously demonstrated that Igl transcription was reduced
in PU.1/Spi-B double-knockout Pro-B cell lines (Schweitzer & DeKoter, 2004). In
summary, we expect that reduced Igk V region transcription in Fraction D Small Pre-B
cells lacking PU.1 and Spi-B results in impaired Igk V region accessibility and impaired
Igk recombination, which lead to a block in B cell development at the Small Pre- B cell
stage. These studies reveal an important role for PU.1 in Igk transcription and
rearrangement, as well as a requirement for PU.1 and Spi-B in B cell development.
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2.4

Material and Methods

2.4.1 Mice
Mb1-Cre mice were described previously (20). Mb1-Cre mice were crossed with
Spi1lox/lox Spib-/- to generate Mb1-CreDPB mice. Mb1+/Cre Spi1lox/lox Spib+/+ (Mb1-CreDP)
and Mb1+/Cre Spi1+/+ Spib-/- or Mb1+/+ Spi1+/+ Spib-/- (DB) mice were used as experimental
controls. C57BL/6 mice were purchased from Charles River Laboratories (SaintConstant, QC, Canada). All experiments were performed in compliance with the Western
University Council on Animal Care guidelines.

2.4.2 Flow Cytometry and Cell Sorting
For spleen and BM analysis, cells were prepared from 6–10-wk-old Mb1-CreDPB,
Mb1-CreDP, DB, and wild-type (WT) mice. RBCs were removed from single-cell
suspensions using hypotonic lysis. Flow cytometric analyses were performed using an
LSR II instrument (BD Immunocytometry Systems, San Jose, CA). Abs were purchased
from eBioscience (San Diego, CA), BioLegend (San Diego, CA), or BD Biosciences
(Mississauga, ON, Canada) and included PE–anti-CD19 (1D3), FITC–anti-BP-1 (6C3),
allophycocyanin–anti-B220 (RA3-6B2), allophycocyanin–anti-IgM (II/ 41), PE–anti-Igk
(187.1), FITC–anti-IL-7R (A7R34), BV421–anti- B220 (RA3-6B2), PE–anti-BP-1
(6C3), FITC–anti-CD24 (M1/69), biotin– anti-CD43 (S7), and PE/Cy5 streptavidin. BM
cell sorting was performed on a FACSAria with FACSDiva software (both from BD).
Data were analyzed using FlowJo 9.7.4 software.

2.4.3 Cell Culture
The 660BM and i660BM cell lines used in this study were described previously
(Christie et al., 2015). Cells were cultured in IMDM (Wisent, QC, Canada) containing
5% IL-7–conditioned medium from the J558L–IL-7 cell line (21), 10% FBS (Wisent),
penicillin/streptomycin/L-glutamine (Lonza, Shawinigan, QC, Canada), and 2-ME
(Sigma-Aldrich, St. Louis, MO). i660BM cells were maintained in 0.5 mg/ml puromycin

71

(BioBasic, Markham, ON, Canada). Cell lines were maintained in 5% CO2 atmosphere
at 37 ̊C.

2.4.4 RNA-Seq Analysis
i660BM cells were induced for 48 h with doxycycline (70 ng/ml) in the presence
of 5% IL-7–conditioned medium described above, and RNA was extracted using an
RNeasy Kit (QIAGEN, ON, Canada). Uninduced cells were used as a control. Paired-end
(mRNA-sequencing stranded) libraries were prepared using Illumina TrueSeq Adapters.
Libraries were sequenced using an Illumina HiSEquation 2000 sequencer in paired-end
mode. Data analysis was performed as described previously (Batista, Li, Xu, Solomon, &
DeKoter, 2017) using the tools available in Galaxy suite (Afgan et al., 2016). Standard
Illumina sequencing adaptors (5’-AGATCGGAAGAGC-3’) and short reads were
removed using Trim Galore! V0.2.8.1 in mate-paired mode with trim low quality: 20;
maximum allowed error rate: 0.1; discard reads that became shorter than length: 20.
Trimmed FASTQ files were aligned to the mouse genome (mm10) using TopHat2 v2.0.9
in mate-paired mode, with mean inner distance between mate pairs: 140 and SD for
distance between mate pairs: 30. Assembled transcript abundance and differential gene
expression were determined using Cufflinks/Cuffdiff v2.1.1. Reference annotation files
were down- loaded from UCSC RefSeq Genes (GRCm38/mm10) in gtf format. Cuff-diff
output genes with a fold change < 0.5 or ³ 0.5 (log2) were classified as significantly
upregulated or downregulated genes, respectively. Transcripts presenting PU.1 ChIP
peaks within 15 kb upstream or downstream of the TSS and exhibiting significant fold
change by RNA- seq were considered PU.1-regulated genes. Functional classification
analysis was performed on predicted PU.1 target genes from the Data- base for
Annotation, Visualization and Integrated Discovery (DAVID) using GOTERM_BP_FAT
(Huang, Sherman, & Lempicki, 2009). Functional protein classification of PU.1regulated genes was determined using the PANTHER classification system (Huaiyu Mi,
Muruganujan, Casagrande, & Thomas, 2013).
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2.4.5 ChIP and ChIP-seq Analysis
i660BM cells were induced for 24 h with doxycycline (70 ng/ml) in the presence
of 5% IL-7–conditioned medium described above. Chromatin was cross-linked with 1%
paraformaldehyde for 10 min, and crosslinking was terminated by the addition of glycine.
Chromatin yielding 150–300 mg was immunoprecipitated using Dynabeads Protein G
(Life Technologies) conjugated to 6 mg of rabbit polyclonal anti-PU.1 Ab (Santa Cruz
Biotechnology, Santa Cruz, CA) or 6 mg of rabbit polyclonal anti-IgG Ab (Abcam, ON,
Canada). Immunoprecipitated chromatin was de–cross- linked and DNA was purified
using a QIAquick PCR Purification Kit (QIAGEN). PU.1 immunoprecipitation was
validated by quantitative RT- PCR (RT-qPCR) using two sets of primers for the E2f1
gene: a positive set targeting the PU.1 binding site on intron 1 of the E2f1 gene and a
negative set targeting a region on intron 4 of the E2f1 gene. Illumina TruSeq DNA
libraries were prepared from two biological replicates of PU.1- immunoprecipitated
chromatin and one sample of input chromatin. Libraries were sequenced using an Illumina
HiSEquation 2000 SR100 sequencer (Genome Quebec Innovation Centre, QC, Canada).
ChIP-seq data analysis was conducted using Galaxy Suite (Afgan et al., 2016). Illumina
sequencing adapters were removed using Trim Galore! Trimmed FASTQ files were
aligned to the mouse reference genome GRCm38/mm10 with Bowtie, reporting only the
best alignment for each fragment (–best) with a maximum number of two mismatches
with an average quality score ³ 70 (Langmead, Trapnell, Pop, & Salzberg, 2009).
Experimental replicate BAM aligned files were merged using merge BAM files in
Galaxy. Peaks were called using MACS1.4.1 with a mappable genome size of 1.8 3 1010
bp (mm10). Peaks were called with a tag size to 100, bandwidth of 300, and a p value
cutoff for peak detection of 1e207. Sequences of regions with significant PU.1 binding
were extracted using extract genomic DNA in Galaxy. Motif discovery was performed
with MEME-ChIP version 4.11.1. Functional analysis of cis-regulatory regions bound by
PU.1 were identified using CEAS (Shin, Liu, Manrai, & Liu, 2009). Heat maps of ChIP
signals surrounding TSSs were generated using deepTools2 (Ramirez, Dundar, Diehl,
Gruning, & Manke, 2014).
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2.4.6 Igk Locus Analysis
Transcription of Igk genes was evaluated from RNA-seq data using Cufflinks and
the GENCODE mouse reference that contains a complete annotation for the Ig gene
segments (Harrow et al., 2006). Average fold change expression of Igk genes was
determined from three replicates for each group (-DOX and +DOX). Igk genes were
classified as upregulated (fold change. 1.0) or downregulated (fold change, 21.0) as a
ratio between induced and control condition. A heat map illustrating the upregulated and
downregulated genes was generated using GENE-E (Broad Institute, Cambridge, MA).
Regions of PU.1 binding were intersected with the reference vM9 GENCODE to correlate
ChIP binding with transcripts using bedtools v2.22.1 (Quinlan & Hall, 2010). Regions
overlapping by ³1 bp were reported as PU.1-bound transcripts and presented as Venn
diagrams generated using InteractiVenn (Heberle, Meirelles, da Silva, Telles, &
Minghim, 2015). RNA-seq and ChIP-seq genome tracks were visualized in the UCSC
genome browser.

2.4.7 PCR and Gene-Expression Analysis
Genomic DNA was prepared from 660BM or i660BM cells after 48 h of PU.1
induction with doxycycline (70 ng/ml) with low (0.1 ng/ml) or high (7.5 ng/ml) IL-7.
RNA was prepared using TRIzol Reagent or an AllPrep DNA/RNA Mini Kit (QIAGEN)
from 660BM or i660BM cells after 48 h of PU.1 induction with doxycycline (70 ng/ml)
in 5% or 2.5% IL-7–conditioned medium. cDNA was synthesized from purified RNA
using an iScript cDNA synthesis kit (Bio-Rad). cDNA was diluted to a concentration of
30 ng/ml in RNase-free water for the RT-qPCR reactions. PCR reactions to detect
Igk rearrangements were performed as previously described (Cobaleda, Jochum, et al.,
2007). RT-qPCR reactions were prepared with specific primers for the genes of interest
using SensiFAST SYBR green (Bioline, London, U.K.), and amplification was performed
on a Rotor Gene 6000 instrument (Corbett Life Sciences, Valencia, CA). Gene expression
was normalized to B2m expression, and fold expression was calculated using the D
threshold cycle method (Livak & Schmittgen, 2001). Primers sequences are shown on
Table 1.
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Table 1. Primer Sequences Used in The Study Described on Chapter 2.
RT-qPCR
Genes

Sequences

B2m

F
R

TGGCTCACACTGAATTCACCCCCA
TCTCGATCCCAGTAGACGGTCTTGG

Bactin

F
R

CCTAAGGCCAACCGTGAAAAG
TCTTCATGGTGCTAGGAGCCA

Hrpt

F
R

TCCTCCTCAGACCGCTTT
TTTTCCAAATCCTCGGCATAATG

Igkv10-96

F
R

GGTCTCCTGTTGCTCTGTTT
CAACTGATGGTGACTCTGTCTC

Igkv12-98

F
R

TATCAGCAGAAACCAGGGAAAT
GATCCACTACCACTGAACCTTG

Igkv1-135

F
R

CTCCAAAGCGCCTAATCTATCT
GCCTCCACTCTGCTGATTT

Igkv4-57

F
R

GTGCCAGCTCAAGTGTAAGT
GCCAGGTTGGATGTGCTATAA

Igkv4-73

F
R

GTGCCAGCTCAAGTGTAAGT
CCAGAAGCCAGGTTGGATATG

Igkv12-44

F
R

CAGGCTGTTGATCTTCAGAGAA
CTCCTCAGCTCCTGGTCTATAA

Igkv6-13

F
R

GGAGTCACAGATTCAGGTCTTT
ACCCTGTCTCCTACTGATGT

Igkv3-5

F
R

CTGCAGAGCCAGTGAAAGT
CACGATAGATGAGGAGTTTGGG

Igkv12-98

F
R

TATCAGCAGAAACCAGGGAAAT
GATCCACTACCACTGAACCTTG

Glk-1

F
R

GAGGGGGTTAAGCTTTCGCCTACCCAC
GTTATGTCGTTCATACTTCGTCCTTGGT

Spi1

F
R

ATTCGCCTGTACCAGTTCCTGC
TGGACGAGAACTGGAAGGTACC

Btk

F
R

ACAGATTCCGAGGAGAGGTGAGG
GGTCCTTCATATACAACCTGGAA
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ChIP-primers
Genes

Sequences

Gapdh- ChIP

F
R

CGTTCACACCGACCTTCACCATTT
GTCTGTTATATGGGCGTCGTGTCA

Hprt -ChIP

F
R

CGTTCACACCGACCTTCACCATTT
GAAAGCAGTGAGGTAAGCCCAAC

E2f1 (positive)-ChIP (Intron 1)

F
R

AGAGATGGGGAAGTGCTTCACG
CGCACTCCCTAGCCATAGGTTC

E2f1 (negative)-ChIP (Intron 4)

F
R

GTTCCAGGACAGTCAGGGCTATACAG
CCATCTCTCCAGTCCTTGGCTTC

Rearrangement PCR
Genes

Sequences

VHJ558
JH4

CGAGCTCTCCARCACAGCCTWCATGCARCTCARC
TCTCAGCCGGCTCCCTCAGGG

Vk
Jk5

GGCTGCAGSTTCAGTGGCAGTGGRTCWGGRAC
ATGCGACGTCAACTGATAATGAGCCCTCTCC

Genotyping
Genes

Sequences

Mb1/Cd79a

F
R

GAGAAGAAGGGACACCAGAATG
GCACTTGGGAGGCAGAAATA

Mb1-Cre

F
R

ATCAGCCACACCAGACACAGAGATC
AGATGCCAGGACATCAGGAACCTG

lox/lox

1
2

CTTCACTGCCCATTCATTGGCTCATCA
GCTGGGGACAAGGTTTGATAAGGGAA

Cd19

F
R

GAGAGGCACGTGAAGGTCATTG
CATGGCTCTGAGCTCCAGTATC
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2.4.8 Statistical Analysis
All data are graphed as mean ± SEM. Statistical analysis was performed with
Prism 5.0 (GraphPad, La Jolla, CA) using ANOVA or the Student t test, as appropriate.
The p values £ 0.05 were considered significant.

2.4.9 Availability of Data
ChIP-seq and RNA-seq data have been submitted to the Gene Expression
Omnibus (https://www.ncbi.nlm.nih.gov/geo/) under accession number GSE87316.
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Chapter 3
3

Deletion of Genes Encoding PU.1 And Spi-B Leads
to B Cell Acute Lymphoblastic Leukemia Associated
with Driver Mutations in Janus Kinases3
Precursor B cell acute lymphoblastic leukemia (Pre-B-ALL) is associated with

recurrent mutations that occur in cancer-initiating cells. There is a need to understand
how these spontaneous driver mutations influence clonal evolution in leukemia. The ETStranscription factors PU.1 and Spi-B (encoded by Spi1 and Spib) execute a critical role in
B cell development and serve as complementary tumour suppressors by opposing the
proliferative events mediated by IL-7R signaling. Here, we used a mouse model to
conditionally delete Spi1 and Spib genes in developing B cells. These mice developed BALL with a median time to euthanasia of 18 weeks. We performed RNA and wholeexome sequencing (WES) on leukemias isolated from the thymus of Mb1-CreΔPB mice
and identified single-nucleotide variants (SNVs) in Jak1, Jak3 and Ikzf3 genes, resulting
in amino acid changes and the gain of early stop-codons. JAK3 mutations resulted in
amino acid substitutions located in the pseudo-kinase (R653H, V670A) and in the kinase
(T844M) domains. Introduction of these mutations into wild-type Pro-B cells conferred
survival and proliferation advantages. We conclude that mutations in Janus kinases
represent secondary drivers of leukemogenesis in the absence of Spi-B and PU.1
transcription factors. This mouse model represents a useful tool to study clonal evolution
and tumour heterogeneity in B-ALL.

3

Text and figures within this section have been adapted from the manuscript under review on Blood

Advances:
Batista, C. R., Lim, M., Laramee, A.-S., Abu-Sardanah, F., Xu, L. S., Hossain, R., & DeKoter, R. P. (2018).
Deletion of genes encoding PU.1 and Spi-B leads to B cell acute lymphoblastic leukemia associated
with driver mutations in Janus Kinases. BioRxiv, 291054. http://doi.org/10.1101/291054
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3.1

Introduction
Acute lymphoblastic leukemia is the most common type of childhood cancer with

approximately 6000 new cases diagnosed in the United States each year (R. Siegel, Ma,
Zou, & Jemal, 2014). Most leukemias originate within the B cell rather than the T cell
lineage (Hunger & Mullighan, 2015; Inaba, Greaves, & Mullighan, 2013). Precursor B
cell acute lymphoblastic leukemia (Pre-B-ALL) is a disease revealed by the presence of
transformed precursor B cells in the blood, bone marrow, and tissues; and is most
prevalent in 1-5 year old patients (C. H. Pui, Robison, & Look, 2008). Most Pre-B-ALL
cases are associated with genetic abnormalities that include chromosomal translocations
or point mutations. In Pre-B-ALL, up to two thirds of genes with point mutations encode
transcriptional regulators such as Pax-5, Ikaros, or EBF1 (Inaba et al., 2013). Pre-B-ALL
cells are frequently arrested at an early stage of development, express interleukin-7
receptor (IL7R), and have high levels of Janus Kinase (JAK)-STAT signaling to sustain
survival and proliferation (Buchner, Swaminathan, Chen, & Muschen, 2015; Mangolini
et al., 2013; Muschen, 2015). Activating mutations of the IL7R gene have been described
in human Pre-B-ALL (Shochat et al., 2011). JAK and IL7R mutations are frequent in
several subtypes of Pre-B-ALL including the recently described disease Ph-like leukemia
(Jain et al., 2017; Roberts et al., 2017). In summary, mutations that activate cytokine
signaling (IL-7R), or impair differentiation signals, function as driver mutations in PreB-ALL.
PU.1 (encoded by SPI1) and Spi-B (encoded SPIB in mice) are transcription
factors of the E26-transformation-specific (ETS) family (Ray et al., 1992). These two
proteins share a conserved DNA binding domain and interact with an overlapping set of
DNA binding sites within the genome (Solomon et al., 2015). PU.1 and Spi-B
complement each others function, and activate multiple genes involved in B cell receptor
signaling (Christie et al., 2015; Garrett-Sinha et al., 1999; S. K. Li, Abbas, Solomon,
Groux, & DeKoter, 2015; Solomon et al., 2015). Lack of these factors in developing B
cells results in a block to B development at the Small Pre-B cell stage associated with
impaired Ig light chain rearrangement (Batista et al., 2017; Christie et al., 2015).
Importantly, conditional deletion of Spi-B and PU.1 in developing B cells leads to high
incidence of B-ALL in mice, but the mechanisms of leukemogenesis in the absence of
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these transcription factors remain undetermined (Sokalski et al., 2011). Thus, PU.1 and
Spi-B are required for B cell development and function as complementary tumour
suppressors in the B cell lineage.
B cell neoplasms, like many cancers, are thought to be diseases in which there is
clonal evolution from a common precursor, in which acquired gene mutations drive an
evolutionary natural selection process (Greaves & Maley, 2012; Nowell, 1976). The
mechanisms by which cancer-initiating cells respond to selection pressures during clonal
evolution have been classified into a number of common hallmarks (Hanahan &
Weinberg, 2011). In response to selection pressure, the genetic makeup of cancerinitiating cells changes during the course of disease due to acquired mutation. Mutations
can be broadly classified as drivers or passengers (Greaves & Maley, 2012; Vogelstein et
al., 2013). Driver mutations are those that provide a growth advantage to a cancer clone,
whereas passenger mutations do not provide a growth advantage. Pediatric B-ALL is less
curable upon relapse due to clonal evolution of the leukemia, resulting in driver mutations
inducing a more aggressive disease (Ferrando & Lopez-Otin, 2017). High levels of
intratumoral heterogeneity of mutations is also a poor prognostic marker for leukemia
(Hu, Sun, & Curtis, 2017). Whole-exome or whole-genome sequencing of Pre-B-ALL
cases is expected to lead to a deeper understanding of the genetic causes of this disease,
ultimately permitting targeted therapy for individual patients (Hunger & Mullighan,
2015).
In this study, we investigated the molecular features of leukemogenesis in a
spontaneous model of B-ALL induced by deletion of genes encoding PU.1 and Spi-B.
We generated Mb1+/CreSpi1lox/loxSpib-/- mice, called here Mb1-CreDPB mice (Batista et
al., 2017). We previously found that Mb1-CreDPB mice developed Pre-B-ALL
characterized by the high expression of IL-7R, with a median time to euthanasia of 18
weeks. Using whole-exome sequencing (WES) and RNA-seq, we identified multiple
single-nucleotide variants (SNVs), most of which were predicted to have a role in the
control of cell proliferation, communication and metabolism. Strikingly, we identified
recurrent SNVs in genes encoding Aiolos, Jak1, and Jak3 in mouse leukemias. Further
analyses revealed that SNVs located in Jak3 resulted in three different types of amino
acid substitutions within the pseudo-kinase domain (R653H, V670A) or kinase domain

80

(T844M). We confirmed the ability of these mutations to provide a survival and
proliferation advantage to normal Pro-B cells. In summary, this study shows that Jak3
mutations are secondary drivers of leukemogenesis in the absence of Spi-B and PU.1.
This mouse model may be useful to determine the effects of molecular targeted therapies
on intratumoral heterogeneity and clonal evolution in B-ALL.

3.2

Results

3.2.1 Deletion of Genes Encoding PU.1 And Spi-B Leads To B Cell Acute
Lymphoblastic Leukemia
We recently reported that deletion of the genes encoding both PU.1 and Spi-B in B
cells under control of the Cd79a (Mb1) promoter (Mb1+/Cre Spi1lox/lox Spib-/- mice,
abbreviated to Mb1-CreDPB) resulted in a severe impairment to B cell development at the
Large Pre-B to Small Pre-B cell transition in the bone marrow of 6-10 week-old mice
(Batista et al., 2017). Mb1-CreDPB mice expressing Cre recombinase and deleted for Spi-B
but homozygous for the wild type Spi1 allele were fertile and healthy. However, Mb1CreDPB mice had a shortened life span, with median survival of 18 weeks, at which point
they required euthanasia due to signs of illness, including lethargy and labored breathing
(Fig. 3.1 A, B). Dissection of euthanized mice revealed enlargement of the spleen and
thymus (Fig. 3.1 A, C, D). Histological analysis revealed that normal spleen and thymus
organization was completely effaced in moribund Mb1-CreDPB mice compared to the
control Mb-1Cre DB mice (Fig. 3.1 E).

81

Figure 3.1. Mb1-CreDPB Mice Develop B Cell Acute Lymphoblastic Leukemia (BALL).
(A) Mb1-CreDPB mice (DPB) mice developed B-ALL characterized by splenic and
thymic enlargement (indicated by arrows). (B) Percentage survival of mice of the
indicated genotypes by weeks elapsed: Mb1+/CreSpi1lox/lox Spib-/- (Mb1-CreDPB, n= 43);
Mb1+/CreSpi1+/+ Spib-/- mice (Mb1-CreDB, n=36) and Mb1+/+Spi1lox/lox Spib-/- (Mb1CreDB, n=14). (C). Comparisons of enlarged spleens and thymuses extracted from Mb1CreDPB mice compared to control DB mice (Mb1+/+ Spi1lox/lox Spib-/-). (D) Spleen (left)
and thymus (right) weight in grams (g) relative to the body weight in WT and Mb1CreDPB mice. WT, n=10 (spleen), 5 (thymus); Mb1-CreDPB, n=11 (spleen), 8 (thymus).
p≤ 0.05 (*), mean ± SEM. (E). Histologic sections (HE) of spleen and thymus illustrating
the lymphocytic infiltration and loss of normal organ structure in Mb1-CreDPB compared
to controls Mb1DB (4x).
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Mb1-CreΔPB

3.2.2 Characterization of Mb1-CreDPB Mice Leukemias Indicates Pro-B
cell to the Pre-B Cell Origin
Flow cytometry analysis was used to determine the stage in which leukemic cells
begin to infiltrate the spleen and thymus of Pre-leukemic Mb1-CreDPB mice. We observed
the presence of B220+CD19+ cells in the spleen and thymus of Mb1-CreDPB mice aged 11
weeks, but not in either C57BL/6 or Mb1DB mice (Fig. 3.2 A, B). At the time of euthanasia
of leukemic Mb1-CreDPB mice aged >15 weeks there were higher frequencies of
B220+CD19+ cells in both organs (Fig. 3.2 A, B). Further analysis seeking to determine the
phenotype of cells infiltrating the spleen and thymus showed that these organs contained
high frequencies of B220+ and CD19+ cells that also expressed c-Kit, CD43, BP-1, and IL7Ra (Fig. 3.2 D). These analyses suggested that these cells were a Pre-B cell-like acute
lymphoblastic leukemia similar to that previously reported in CD19-CreDPB mice (Sokalski
et al., 2011) or mice deleted for genes encoding PU.1 and IRF4/8 (S. H. M. Pang et al.,
2016).
Next, leukemic cells obtained from the spleen or thymus of Mb1-CreDPB mice were
characterized to determine expression of cell surface IgM and Igk. Analysis of leukemias
from Mb1-CreDPB mice revealed that at least 74% of individual mouse leukemias did not
express IgM or Igk at the cell surface (Fig. 3.2 E, bottom; F, left panel). Conversely, 26%
of leukemias from Mb1-CreDPB mouse spleen or thymus had cell surface expression of both
IgM and Igk (Fig. 3.2 E, top; F, left panel). In contrast, similar analysis performed on CD19CreDPB mice showed that 78% of leukemias had IgM and Igk on the cell surface (Fig. 3.2
F, right panel). Most leukemias isolated from Mb1-CreDPB mice had IgH rearrangements,
although fewer leukemias expressed IgM at the cell surface (Fig. 3.2 C). In summary, these
results show that leukemia cells begin to appear in thymus and spleen of Mb1-CreDPB mice
after 11 weeks of age. All leukemias in Mb1-CreDPB mice (11-26 weeks of age) expressed
IL-7R, but most did not express Ig on their cell surface, suggesting that these cells resembled
Pro-B or Large Pre-B cells.
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Figure 3.2. Most Leukemias from Mb1-CreDPB Mice Resemble Pro-B cells and Do Not
Express Either IgM Or Igk at the Cell Surface.
(A) Representative flow cytometric analysis for the presence of CD19+ B220+ B cells in
the spleen of C57BL/6 mice; 11 weeks old Mb1-CreDB mice and Mb1-CreDPB mice (left
panels); and >15 weeks old Mb1-CreDPB mice (right panel). (B) Representative flow
cytometric analysis for the presence of CD19+ B220+ B cells in the thymus of C57BL/6
mice; 11 weeks old Mb1-CreDB mice and Mb1-CreDPB mice (left panels); and >15
weeks old Mb1-CreDPB mice (right panel).

(C) PCR detection of heavy chain

rearrangements (J558-JH4) in leukemia B cells extracted from the thymus of Mb1CreDPB mice (575-411). B cells extracted from WT mouse (C57BL/6) were used as
control and presented the four types of rearrangements. Cd79 gene was used as control
for DNA quality. (D) Representative flow cytometric analysis of leukemic cells from
Mb1-CreDPB mice gated on CD19+ B220+ cells showed that leukemias expressed IL-7R
on the cell surface (top and bottom). (E) Representative IL-7R+ leukemias expressing IgM
and Igk, (top, Ig+) and those not expressing IgM and Igk (bottom, Ig-). (F) Percentage of
leukemias expressing IgM and Igk (Ig+) or not expressing IgM and Igk (Ig-). Left panel,
Mb1-CreDPB mice, n=14 (spleen) and n=8 (thymus). Right panel, CD19-CreDPB mice,
n=9 (thymus).
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3.2.3 Whole-Exome Sequencing (WES) Identified Somatic Nucleotide
Variants in Leukemias Generated in the Lack of Spi-B and PU.1
As described above, Mb1-CreDPB mice had a variable time to requirement of
euthanasia as well as heterogeneity in Ig expression status of leukemias (Fig. 3.1 and 3.2).
This variability suggested that secondary driver mutations were required to induce
leukemia in addition to the initiating lesion of Spi1/Spib deletion. In order to discover
potential driver mutations in Mb1-CreDPB mouse leukemias, we performed wholeexome sequencing (WES) analyses of three mouse tumours, 853, 854, and 857, as well
as on matched genomic tail DNA as a control. FACS analyses were performed in the
leukemias submitted for sequencing and shows heterogeneity of leukemias (Fig. 3.3 AC). Single Nucleotide Variants (SNVs) for each of the samples were identified by
comparing leukemia and control tail DNA exome sequences using the Strelka somatic
variant caller (Saunders et al., 2012).
The number of SNVs identified by Strelka differed for each of the tumours, where
sample 854 showed the highest number of SNVs (3,887) (Fig. 4.1 A-C | Chapter 4).
Samples 853 and 857 presented a very similar number of SNVs, totaling 2,558 and 2,465,
respectively. Although the tumours had a variable number of SNVs, the distribution of
the SNVs by chromosome followed a similar pattern in which chromosome 2 showed the
highest frequency of SNVs, followed by chromosome 11, chromosome 1 and
chromosome 7 (Fig. 4.1 A-C | Chapter 4).
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Figure 3.3. Characterization of Mb1-CreDPB Leukemias After Whole-Exome
Sequencing Analysis (WES).
(A) DNA and RNA were isolated from leukemic cells extracted from thymus of leukemic
mice. Samples 853, 854 and 857 were submitted to WES and RNA sequencing,
respectively. (B) Weeks of survival and weight of the organs extracted from leukemic
Mb1-CreDPB mice. Samples 853 and 854 were used for sequencing experiments. (C)
FACS characterization (IgM, x-axis; Igk, y-axis; Gated on CD19+ B220+ cells) of
leukemic mice in which DNA and RNA were isolated for sequencing. C57BL/6, control;
853, 854, 857, leukemic Mb1-CreDPB; FMO = fluorescence minus one.
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3.2.4 Identification of the “High Confidence Somatic Nucleotide Variants
(SNVs)” in Mb1-CreDPB mice Leukemias
In order to increase confidence in the SNVs identified by Strelka and to reduce the
number of SNVs without a potential biological function, somatic variants were called with
a second variant discovery method, Mutect (Cibulskis et al., 2013). Mutect detected fewer
SNVs than Strelka (Fig. 3.4A-C). The overlap of SNVs identified by both methods was used
to identify high confidence SNVs. Using this strategy, we found that the number of SNVs
was reduced, resulting in 183 SNVs for sample 853, 293 SNVs for sample 854, and 199
SNVs for sample 857. High confidence SNVs were annotated using the mouse genome
(mm10) using the SnpEff tool, which also enabled the prediction of the biological effect of
the variants (Cingolani et al., 2012). We found that the majority of the high confidence SNVs
were classified as having a MODIFIER or MODERATE deleterious impact while a few
SNVs were classified as HIGH impact (Fig. 3.4D).
We looked at the effect of SNVs classified as MODERATE and HIGH, and found
that most of the SNVs classified as MODERATE resulted in missense variants; while the
few SNVs predicted as having HIGH impact caused the gain or loss of stop codons, or
alterations in splice acceptor or donor sites, defined by two bases before exon start or end,
respectively (Fig. 3.4E). We next investigated whether there were common SNVs among
the three mouse tumours sequenced. Samples 854 and 857 showed common SNVs in the
genes Sntg1, Brd8, Lrp5 and Slco1b2 (Fig. 3.4F). Samples 853 and 854 showed common
SNVs in the genes Ryr2 and Skint6. Finally, samples 853 and 857 showed common SNVs
in the genes Ikzf3 and Jak3 (Fig. 3.4F). Interestingly, sample 854 presented a unique SNV
in the Jak1 gene. Sanger sequencing of samples 853, 854 and 857 confirmed the presence
of SNVs identified by WES in the Jak3, Jak1 and Ikzf3 genes (Fig. 3.5) Interestingly, Ikzf3
and Jak3 are well-characterized driver mutations in human Pre-B cell acute lymphoblastic
leukemia (Iacobucci & Mullighan, 2017). The identification of common Ikzf3 and Jak3
SNVs suggests that this approach is effective at identifying potential driver mutations.
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Figure 3.4. Identification of the “High Confidence Somatic Nucleotide Variants (SNVs)”
in Mb1-CreDPB Mice Leukemias.
(A, B and C) SNVs identified by two different variant caller methods, Strelka and Mutect,
were combined and overlapping SNVs were classified as “High confidence SNVs”. (D)
Classification of “High confidence SNVs” for impact. Graph shows the number of SNVs
classified according to impact. (E) Predicted biological effect of the “High confidence
SNVs” classified as having MODERATE and HIGH impact. (F). Venn diagram showing
the overlap among “High confidence SNVs” identified in the three-individual mouse
leukemias. Genes containing common SNVs among the three mouse leukemias.
Leukemias “853” and “857” presented common SNVs in the Jak3 and Ikzf3 genes.
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Figure 3.5. Sanger Sequencing Confirmed the Presence of SNVs Identified by WES
and Revealed Tumours Heterogeneity.
PCR amplification of the region containing the SNVs were performed on cDNA
synthesized from RNA extracted from mouse tumours. PCR product was sent to Sanger
sequencing using specific primers targeting the region of interest. (A); Sanger sequencing
of region containing Ikzf3 SNV identified in sample 857, transition C-T; (B) Ikzf3 SNV
identified in sample 853, transition C-T; (C) Jak1 SNV identified in the sample 854;
transition G-T; (D) Jak3 SNV identified in the sample 853; transition G-A. (E) Jak3 SNV
identified in the sample 857; transition C-T. Chromatograms for individual samples are
shown for each SNV investigated. Heterozygous SNVs present two peaks at one location
(Fig. 3.6 D; sample 853), while homozygous variations presented a single peak (Fig. 3.6
B, sample 853).
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3.2.5

Mutations in Janus Kinase 1 And 3 (Jak1/Jak3) and Aiolos (Ikzf3)
Genes are Potential Secondary Drivers of Leukemogenesis in
Mb1-CreDPB Mice
As cancer driver genes would be expected to contain mutations and be expressed

(Vogelstein et al., 2013), we also performed RNA-sequencing analysis on leukemias 853,
854, and 857 in order to assess gene expression levels. To filter data based on levels of gene
expression, Fragments Per Kilobase of transcript per Million mapped reads (FPKM) was
determined from RNA-seq data using Cufflinks. FPKM was plotted against variable allelic
frequency (VAF) determined using Strelka (Saunders et al., 2012) for three mouse leukemias
853, 854, and 857. In each of the three samples there were highly expressed genes that also
had high VAF (Fig. 3.6 A-C). Importantly, sample 853 had high FPKM and VAF for variants
in Jak3 and Ikzf3 (Fig. 3.6 A). Sample 854 had high FPKM and VAF for a variant in Jak1
(Fig. 3.6 B). Finally, sample 857 had high FPKM and VAF for variants in Jak3 and Ikzf3
(Fig. 3.6 C). The elevated expression levels added to the high VAF of Jak1, Jak3 and Ikzf3
genes in Mb1-CreDPB mice leukemias supports the hypothesis that these variants represent
secondary driver mutations.
Next, we sought to define the biological processes in which mutated genes could be
involved by performing gene ontology analysis in genes with VAF greater than 20%, using
PANTHER Gene List Analysis (H Mi, Muruganujan, Casagrande, & Thomas, 2013). We
observed a pattern for all three samples where most of the genes were categorized in two
major biological processes, “Cellular Process” and “Metabolic Process”. Specifically, genes
within “Cellular Process” were subcategorized in subprocesses such as cell communication,
cell proliferation and cell cycle (Fig. 3.6 D-F). Genes as Cit, Cdk9 and Stag1 are related to
the control of cell cycle by regulating cytokinesis, transcription and cohesion of sister
chromatids after DNA replication, respectively. Importantly, Smarcb1 encodes a core
subunit protein of the ATP-dependent SWI/SNF chromatin remodeling complex, and was
previously identified as a tumor suppressor (Tokheim, Papadopoulos, Kinzler, Vogelstein,
& Karchin, 2016). Nap1l4, encodes a member of the nucleosome assembly protein and has
a role as a histone chaperone. Genes involved in cell communication and adhesion, as
Cntnap5b, Fras1, Sdk1 and Magi, were also enriched in our pathway analysis. In summary,
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Jak3 and Ikzf3 mutations were identified as potential drivers of leukemogenesis in Mb1CreDPB mice, based on the observation that these genes are mutated in two of three
leukemias, have high VAF, and have high levels of expression.
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Figure 3.6. Integration of RNA-Seq and Whole-Exome Sequencing (WES) Allows the
Identification of Secondary Driver Mutations.
(A, B and C). Scatter plot correlating the levels of gene expression in Fragments Per
Kilobase of Transcript per Million of reads mapped (FPKM log10) and the Variant Allele
Frequency (VAF) for genes in which FPKM was greater than zero. Leukemias 853, 854
and 857 are shown, respectively. (D, E and F). Biological Pathway Analysis in genes with
VAF equal or greater than 20% was performed using Panther – Gene List Analysis.
Diagram shows the number of genes enriched according the biological process.
Enrichment for genes related to “Cellular Process” and “Metabolic Process” was
observed for the three samples analyzed. List shows that genes enriched within “Cellular
Process” were mostly classified in sub processes as “Cell Cycle”, “Cell Communication”
and “Cell Proliferation”.
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3.2.6 Recurrent Mutations in Janus Kinase 3 (Jak3) and Janus Kinase 1
(Jak1) in Leukemias from Mb1-CreDPb Mice
Analysis of the impact of variants on protein expression showed that SNVs in
leukemias 853 and 857 resulted in coding changes in Jak3 (R653H, V670A, and/or T844M)
while the SNV in Jak1 in sample 854 resulted in a V657F substitution (Fig. 3.7 A, B). These
genes encode for Jak1 and Jak3 that are critically required for signaling through cytokine
receptors IL7R and CRLF2 (Babon, Lucet, Murphy, Nicola, & Varghese, 2014).
Comparison of Jak3 and Jak1 protein sequences among six different vertebrates showed that
amino acids that underwent substitution in consequence of a SNV were highly conserved
between these species (Fig. 3.7 A, B).
To determine whether these variants represent recurrent leukemia driver mutations,
we performed Sanger sequencing on a total of 19 Mb1-CreDPB leukemias using primers
flanking the regions containing the SNVs identified by WES. Interestingly, this examination
revealed that Jak3 R653H mutation was detectable in 5/19 leukemias analyzed. Jak1
mutations V657F or V655L showed even higher recurrence than Jak3 mutation, being
detectable in 10/19 leukemias (Fig. 3.7 D). Ikzf3 mutations were detected only in samples
853 and 857, confirming the exome sequencing (Fig. 3.7 D). In summary, these data show
that leukemia in Mb1-CreDPB mice was accompanied by recurrent secondary driver
mutations in Jak1 and Jak3.
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Figure 3.7. Mutations Occur in Conserved Regions of Jak1 and Jak3 Genes.
(A, B and C; left) Schematic shows the protein domains of Jak3, Jak1 and Aiolos (Ikzf3).
Amino acids substitutions caused by single nucleotide substitutions identified in the
whole-exome sequencing in samples 853, 854 and 857 are also indicated.
(A, B and C; right) Blast analysis comparing Human (Homo sapiens), Mouse (Mus
musculus), Rat (Rattus norvergicus), African Elephant (Loxodonta africana), Giant
Panda (Ailuropoda melanoleuca), Atlantic Salmon (Salmo salar), Zebrafish (Danio
rerio), Tropical Frog (Xenopus tropicalis) protein sequences for Jak1, Jak3 and Aiolos
shows that amino acids which undergo substitution in consequence of a single nucleotide
variation are highly conserved between species. (D) Sanger sequencing screening for the
presence of amino acids substitutions in Jak1 (V657F and V655L), Jak3 (T844M and
R653H), and Aiolos (R137* and H195Tyr) in a panel of nineteen leukemias extracted
from Mb1-CreDPB mice. Filled boxes indicate samples which mutations were identified
by Sanger Sequencing.
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3.2.7 R653H, V670A, and T844M Amino Acid Substitutions in Jak3
Confers Survival and Proliferation Advantages
We next tested whether R653H, V670A, and T844M amino acid substitutions in
Jak3 were able to confer growth advantage to normal cells. Site-directed mutagenesis was
used to introduce these mutations to the wild-type mouse Jak3 coding region in an
MSCV-IRES-GFP vector (a kind gift from Dr. Kevin D. Bunting). Pseudovirus was
generated to spin-infect wild-type Pro-B cells that grow in cultures containing IL-7 and
ST2 stromal cells. Pro-B cells were also infected with MSCV-Jak3 and a MSCV- empty
vectors as controls. Following infection, the cell lines were cultured at high (5%
conditioned medium) or low IL-7 (0.5%). Flow cytometry was performed every two days
for 14 days to determine the frequency of GFP+ cells. Pro-B cells infected with Jak3
mutations R653H, V670A, or T844M outgrew uninfected or control infected Pro-B cells
at both low and high IL-7 concentration (Fig. 3.8 A, B). Next, in order to verify whether
Jak3 mutations resulted in greater proliferation, cells infected with mutant Jak3 were
plated at the initial concentration of 1x105 cells/ml in conditions of low and high IL-7.
Cell numbers and the percentage of viable GFP+ cells were determined after cells were
kept in culture for the period of four days. At low IL-7 concentration, Pro-B cells infected
with Jak3 R653H, V670A, and T844M mutations showed a significant increase in the
number of GFP+ cells after four days in culture (Fig. 3.8 C, D). Therefore, we concluded
that T844M, R653H and V670A amino acids substitutions increased the proliferation of
Pro-B cells in conditions of low IL-7. Taken together, these data indicate that Jak3
mutations identified in these analyses conferred survival and growth advantage to Pro-B
cells, consistent with a role as driver mutations.
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Figure 3.8. JAK3 Mutations Confer Growth Advantage and Increased Proliferative
Potential in Pro-B cells.
(A and B) Percentage of GFP+ cells over the course of 14 days after infection with MSCVempty, MSCV-JAK3, MSCV-T844M, MSCV-R653H, MSCV-V670A or MSCVV670A/T844M in conditions of low (0.5%) and high (5%) IL-7, respectively. (C and D)
Absolute number of viable GFP+ cells after four days in culture under conditions of low
(0.5%) and high (5%) IL-7. Cells were previously infected with either MSCV-empty,
MSCV-JAK3,

MSCV-T844M,

MSCV-R653H,

MSCV-V670A

V670A/T844M. Data is presented as number of cells/ml; n=3.
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3.3

Discussion
In this study, we showed that Mb1-CreDPB mice develop precursor B-ALL that

is detectable by 11 weeks of age and results in the requirement for euthanasia at a median
of 18 weeks. The latency of 11-18 weeks, and variable frequency of leukemias expressing
Ig, showed that there was clonal tumour heterogeneity, and suggested that secondary
driver mutations were required for disease progression. By characterizing the mutation
landscape of Mb1-CreDPB leukemias using whole exome sequencing coupled with RNAsequencing, we discovered that mutations in Jak1 and Jak3 represent recurrent secondary
driver mutations. Introduction of mutant Jak3 into wild type cells was sufficient to
promote growth in response to low IL-7 concentrations. Taken together, these results
showed that deletion of genes encoding PU.1 and Spi-B result in leukemia with
predisposition to additional de novo driver mutations in genes encoding Janus kinases.
Dysregulation of PU.1 and/or Spi-B expression are known to be involved in
human leukemia and have been previously established as tumor suppressors in mouse
models (S. H. M. Pang et al., 2016; Sokalski et al., 2011). Minimal reductions in PU.1
expression were sufficient to induce a preleukemic condition in hematopoietic stem cells
(Will et al., 2015). Whole exome sequencing and whole genome sequencing studies have
revealed that inactivating mutations in genes encoding PU.1 and Spi-B are detectable but
infrequent in human leukemia (Mullighan et al., 2007, 2011). In contrast, PU.1 levels are
repressed by frequently occurring chromosomal abnormalities such as FLT3 internal
tandem duplication (FLT3-ITD) (Mizuki et al., 2003) and RUNX1-ETO fusion (Vangala
et al., 2003). Spi-B levels are repressed by ETV6-RUNX1 chromosomal fusion (S. H. M.
Pang et al., 2016). It is not known how reduced PU.1 and/or Spi-B might lead to
acquisition of secondary driver mutations. However, PU.1 and Spi-B are involved in
attenuating IL-7R signaling in developing pro- and Pre-B cells. Target genes of PU.1 and
Spi-B involved in regulating IL-7-induced proliferation include Btk encoding the tumour
suppressor Bruton tyrosine kinase (Christie et al., 2015), and Blnk encoding B Cell Linker
Protein (L. S. Xu et al., 2012). Btk and Blnk work together to attenuate IL-7R signaling
in developing B cells (Clark et al., 2014). We speculate that mutagenesis in Mb1-CreDPB
is associated with genomic instability due to uncontrolled cell proliferation. Interestingly,
a similar disease is induced by combined deletion of PU.1 and IRF4, suggesting a

105

common axis of gene regulation by PU.1/Spi-B and PU.1/IRF4 (S. H. M. Pang et al.,
2016).
We identified a number of single nucleotide variants (SNVs) in our analysis,
which suggest that several rounds of mutational events contributed to leukemogenesis.
To select for potential leukemia initiator lesions, we focused our attention on genes that
were highly expressed and had high variant allelic frequencies (VAF), reasoning that
genes within this category are likely to have originated earlier in leukemia progression.
Our analyses identified Aiolos (Ikzf3), Jak1 (Jak1) and Jak3 (Jak3) as potential secondary
driver mutations. These genes are involved in signaling downstream of multiple cytokine
receptors during B cell development. Cytokine receptor genes are commonly mutated in
human B cell acute lymphoblastic leukemias (Ma et al., 2018), and mutations in Jak3 and
Ikzf3 have recently emerged as novel mutated genes in high-risk B-ALL (J. Zhang et al.,
2011). In particular, our analysis focused on R653H, V670A, and T844M mutations in
Jak3. Jak3 R653H and V670A mutations were recently observed in B-ALL generated in
activation-induced cytidine deaminase (AID) deficient mice (Auer et al., 2017). Human
equivalents of Jak3 R653H and V670A have been described in human ALL (R657Q,
V674F), and furthermore have been shown to function by activation of proliferation in
response to interleukin-7 (Losdyck et al., 2015). Importantly, human JAK3 V674F is
sufficient to induce T-cell acute lymphoblastic leukemia when retrovirally delivered to
hematopoietic precursors (Losdyck et al., 2015). Jak1 missense mutations V655L or
V657F were also detected in 10 of 19 leukemias in our analysis. Jak1 V657F also
corresponds to a human JAK1 mutation that is a frequent driver in human B-ALL (V658F)
(Hornakova et al., 2009). Interestingly JAK1 V658F mutation has been previously
observed in T-cell acute lymphoblastic and acute myeloid leukemias (Kralovics et al.,
2005). V658F is also thought to be paralogous to the JAK2 V617F mutation that functions
as a driver in more than 95% of cases of polycythemia vera (Bandaranayake et al., 2012).
In summary, the mutations in Jak1 and Jak3 identified in this study are relevant to human
leukemia.
Taken together, this study confirms that leukemia in Mb1-CreDPB mice is
accompanied by de novo recurrent secondary driver mutations in the Janus Kinase
signaling pathway. Mutations in the JAK signaling pathway are recurrent in human
leukemia including the recently discovered Ph-like classification that represents a high
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priority for discovering new therapies (Jain et al., 2017; Roberts et al., 2017). In order to
study the genetic clonal evolution that underlies diseases such as Ph-like leukemia, there
is still a need for mouse models. In order to advance understanding, mouse models should
have the following characteristics: 1) They should develop leukemias with high
penetrance and reproducibility, 2) they should replicate the genetic and molecular
heterogeneity of tumors and involve de novo mutations 3) they should occur in immune
competent mice, and 4) they should mimic that clinical behaviour of human disease
(Jacoby et al., 2014; Kohnken et al., 2017). The Mb1-CreDPB mouse model develops BALL with 100% penetrance by 18 weeks of age that is driven by heterogeneous driver
mutations. This mouse model may be useful to determine the effects of targeted molecular
therapies on intratumoral heterogeneity and clonal evolution in B-ALL.

3.4

Material and Methods

3.4.1 Mice and Breeding
Mb1-Cre mice have been described previously (Hobeika et al., 2006). For this
study, Mb1-Cre mice were crossed with Spi1lox/lox Spib-/- to generate Mb1+/Cre Spi1lox/lox
Spib-/- mice (also referred to as Mb1-CreDPB mice). C57BL/6 mice were purchased from
Charles River Laboratories (Saint-Constant, QC, Canada). Mb1+/CreSpi1lox/lox Spib+/+
(referred to as Mb1-CreDP) and Mb1+/CreSpi1+/+ Spib-/- or Mb1+/+Spi1+/+ Spib-/- (referred
to as Mb1-CreDB) mice were used as experimental controls. Mice were fed with regular
chow and tap water ad libitum and housed with a 12-h light–dark cycle. Mice showing
signs of illness were euthanized and examined for spleen, thymus and lymph node
enlargement and analyzed as described below. All experiments were performed in
compliance with the Western University Council on Animal Care.

3.4.2 Histology and Microscopic Analysis
Mb1-CreDPB mice showing signs of disease were euthanized by CO2 and spleen
and thymus were removed for histological analysis. Spleen and thymus removed from
Mb1-CreDB mice were used as control. Organs were fixed in 10% buffered formalin.
Tissues were paraffin embedded, sectioned, and stained with hematoxylin and eosin.
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High-resolution micrographs were captured using a Q-Color3 digital camera (Olympus,
Markham, ON, Canada).

3.4.3 Flow Cytometry
Single cell suspensions were prepared from enlarged spleen and thymus from
Mb1-CreDPB mice. Red blood cells were removed from single-cell suspensions using
hypotonic lysis. Flow cytometric analyses were performed using a FACSCanto or LSRII
instrument (BD Immunocytometry Systems, San Jose, CA). Antibodies were purchased
from eBioscience (San Diego, CA), BioLegend (San Diego, CA), or BD Biosciences
(Mississauga, ON, Canada) and included PE-anti-CD19 (1D3), FITC-anti-BP-1 (6C3),
APC-anti-IgM (II/ 41), PE-anti-Igk (187.1), FITC-anti-IL-7Ra (A7R34), BV421–antiB220 (RA3-6B2), PE–anti-BP-1 (6C3). Data were analyzed using FlowJo 9.1 software
(Tree Star, Ashland, OR).

3.4.4 Whole-Exome Sequencing
Three matched-tumour and tail mouse samples (853, 854 and 857) had genomic
DNA isolated using Wizard Genomic DNA Purification Kit (Promega Corporation,
Madison WI). Whole-Exome Sequencing was performed by McGill University and
Génome Québec Innovation Centre (Montreal, Canada). The SureSelectXT Mouse All
Exon kit (Agilent Technologies, Mississauga, Canada) was used to perform exome target
capture. Paired-end DNA library preparation was performed using SureSelectXT Target
Enrichment System. An Illumina HiSeq4000 instrument was used to perform the wholeexome sequencing. BAM files were converted to Fastaq format on Galaxy suite using
“SAMtofastaq” (Afgan et al., 2016) tool. Fastaq reads had Illumina Adaptors were
removed using Trim Galore!. Trimmed reads were aligned to the mouse reference genome
(mm10) using Bowtie. BAM aligned files were used as input for single somatic variant
callers. Somatic variants of three matched-tumour mouse samples were called by using
two independent methods, Strelka and Mutect (Cibulskis et al., 2013; Saunders et al.,
2012). For both methods, variants were called using the standard settings recommend by
the package documentation. VCF files containing the somatic nucleotide variants (SNVs)
and Small insertions and deletions (INDELs) generated by Strelka and Mutect were
further filtered following the criteria ‘passed’ or ‘keep’ for the Strelka and Mutect outputs,
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respectively. Filtered VCF files outputted by Strelka and Mutect were intersected using
VCFtools and annotated using the SnpEff (Cingolani et al., 2012) package using the
mouse genomic annotation (mm10). Annotated variants were classified according the
variant impact in HIGH, MODERATE, MODIFIER and LOW, and overlapping variants
among the three samples were determined. Independently, outputs generated by Strelka
and Mutect were also annotated using the SnpEff tool for further analysis.

3.4.5 RNA Sequencing
RNA was extracted from thymic tumours 853, 854 and 857 using RNeasy Kit
(QIAGEN, ON, Canada). RNA-sequencing was performed by McGill University and
Génome Québec Innovation Centre (Montreal, Canada). Paired-end (mRNA-sequencing
stranded) libraries were prepared using Truseq stranded total RNA library prep kit.
Libraries were sequenced using an Illumina HiSeq4000 PE100 instrument. Data analysis
was performed as described previously (Batista et al., 2017). In summary, Standard
Illumina sequencing adaptors were removed using Trim Galore!. Trimmed Fastaq reads
were aligned to the mouse reference genome version mm10 using TopHat2 (Trapnell et
al., 2012) in mate-paired mode using Galaxy suite. Assembled transcript abundance was
determined as previously using Cufflinks (Trapnell et al., 2012).

3.4.6 Sanger Sequencing
RNA extracted from 20 thymic leukemias was reversed transcribed to
complementary DNA using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Primers
flanking the Ikzf3, Jak3 and Jak1 mutations identified by WES were designed using
Primer-BLAST. cDNA was used as a template for PCR reactions using specific primers
(Table 2). PCR reactions were run in a 1.5% agarose gel and the PCR products were
excised and purified from the gel using QIAquick Gel Extraction Kit (QIAGEN, ON,
Canada). Purified DNA was submitted for Sanger sequencing at London Regional
Genomics

Centre,

Western

University

(London,

ON,

Canada).

Sequencing

chromatograms and DNA sequences were analyzed in the software 4Peaks (Mekentosj,
Amsterdam).
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Table 2. Primer Sequences Used in The Study Described in Chapter 3.

SNVs/Consequences

Reference Sequence

Gene

Sequences

Product length

SNV Position 101163673; Alteration C-A

NC_000070.6 (JAK1 DNA)

JAK1

F
R

AAAGTCCTAGACCCCAGCCAC
CGCTCTATGCACTCTTGCCTG

401

SNV Position 71685437; Alteration C-T
T844M (857)

NC_000074.6 (JAK3 DNA)

JAK3

F
R

CGAGTCCTCGAGATGAGCTGT
GGTACTCCATGCCCTTGCAGAT

432

SNV Position 71684008; Alteration G-A
R653H (853)

NC_000074.6 (JAK3 DNA)

JAK3

F
R

GCATCATGGTGCAGGAATTTGT
CGTTGAGGTCTCTGAGGATAGC

549

SNV Position 98488858; Alteration G-A
SNV Position 98490344; Alteration G-A

NC_000077.6 (IKZF3 DNA)

IKZF3

F
R

ACACGTGCCCTATGACAACA
GAGGCATCGAGCTTTTTCGC

503
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3.4.7 DNA Constructs and Site-Directed Mutagenesis
The mouse MSCV-IRES-GFP-JAK3 plasmid was kindly provided by Dr. Kevin
D. Bunting. T844M, R653H, and V670A mutations were generated by site-directed
mutagenesis using Q5® Site-Directed Mutagenesis Kit (New England BioLabs, Ipswich,
MA). Site-directed mutagenesis primers for each one of the specific mutations were
designed using NEBaseChanger tool. Mutations were confirmed by Sanger Sequencing
before retroviral production and spinoculation.

3.4.8 Retroviral Production and Infection
Retroviral supernatants for wild-type Jak3, and T844M, R653H, V670A mutants
were generated Platinum-E retroviral packaging cells (Morita, Kojima, & Kitamura,
2000) using PEIPro transfection reagent (PolyPlus, New York, NY). 10 µg of MSCV
plasmid were cotransfected with 4 µg pECO plasmid (Clontech, Mountain View, CA).
Plasmid DNA was mixed with polyethyleneimine (PEI) at a 2:1 PEI/DNA ratio and
applied to 3 × 106 cells in a 10-cm plate. The medium was changed after overnight
incubation, and virus-containing supernatant was collected 48 hours after medium
change. Wild-type Pro-B cells were infected by spinoculation with 1 mL of viral
supernatant containing 10ul of polybrene at the concentration of 10mg/ml. Cells were
centrifuged at 3000 × g for 2 hours at 30°C and allowed to recover for 24 hours before
medium change and infection was confirmed by flow cytometric analysis for GFP.

3.4.9 Cell Culture
Wild-type and Jak3 mutant-infected Pro-B cell lines used in this study were
cultured in IMDM (Wisent, QC, Canada) containing 10% FBS (Wisent), 1X
penicillin/streptomycin/L-glutamine (Lonza, Shawinigan, QC, Canada), and 5 x 10-5 M
b-mercaptoethanol (Sigma-Aldrich St. Louis, MO). Media also contained 5% or 0.5%
conditioned medium from the IL-7 producing cell line J558-IL-7 (Winkler, Rolink,
Melchers, & Karasuyama, 1995). Cell lines were maintained in 5% CO2 atmosphere at
37˚C.
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3.4.10

Availability of Data

WES data is available from the Sequence Read Archive, accession SRP136503
(https://www.ncbi.nlm.nih.gov/sra/SRP136503). RNA-seq data is available from the Gene
Expression Omnibus, accession GSE112506.

3.4.11

Statistical Analysis
All data reported in this study were graphed as mean ± SEM. Statistical analysis

was performed using Prism 5.0 (Graphpad Software, La Jolla, CA) using ANOVA or
Student’s t test. Values with p ≤ 0.05 were considered significant, where p ≤ 0.05 (*), p
≤ 0.01 (**), p ≤ 0.001 (***), p≤ 0.0001 (****).
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Chapter 4

4

Deletion of Spi-B and PU.1 is Strongly Associated with C•G
> A•T Genomic Transversions
The absence of Spi-B and PU.1 in developing B cells causes a severe block in the

development of B lymphocytes (Chapter 2) and generates B cell acute lymphoblastic
leukemia associated with the presence of secondary driver mutations in the Janus Kinase
proteins (Chapter 3). Another interesting observation from these studies, was the robust
presence of C•G > A•T genomic transversions in leukemias initiated as a consequence of
deletion of Spi-B and PU.1. In this Chapter, the etiology of leukemogenesis in the absence
of these factors is further explored, extending the current knowledge regarding mutational
signatures and their association with the genetic mechanisms contributing to
leukemogenesis.

4.1

Introduction
Somatic mutations within cancer genomes arise as a result of many processes such

as infidelity of the DNA replication machinery, enzymatic modifications of DNA,
defective DNA repair and endogenous or exogenous exposures to mutagens (Greenman
et al., 2007). Bulky somatic mutations can be associated with known cancer etiologies,
such as tobacco smoking in lung cancers, UV light in skin cancers and DNA mismatch
repair in some colorectal cancers (Alexandrov et al., 2013). The somatic mutational
pattern in cancers has been demonstrated to be an important tool to define the etiology of
the mutational processes leading to carcinogenesis. The recent advances in next
generation sequencing, allowed an extensive evaluation of thousands of somatic
mutations within single cancers. Analysis of mutational catalogues of 7,042 primary 30
different classes of cancers combined with normal DNA from the same individuals, has
generated a repertoire of mutational signatures and their associated processes
(Alexandrov et al., 2013). Twenty-one mutational signatures have been described by this
analysis, however while the mechanistic basis of some signatures seems to be understood,
for many other cancer types, their etiology remains unknown (Alexandrov et al., 2013).
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The current understanding regarding the somatic signatures associated with
leukemias and lymphomas is limited. According to Alexandrov et al., 2013, the signatures
19, 6 and 9 have been enriched in leukemias and lymphomas. Signature 19 is associated
with age related processes, while signature 6 is caused by over activity of members of the
APOBEC family of cytidine deaminases, which convert cytidine to uracil, coupled with
activity of the base excision repair and DNA replication machineries (Alexandrov et al.,
2013). Signature 9, which has been observed in chronic lymphocytic leukemia and B cell
lymphomas, is mostly characterized by T>G transversions in association with cancers
which have undergone somatic Ig hypermutation (Alexandrov et al., 2013).
Therefore, we started exploring the mechanisms by which leukemogenesis arise,
in the absence of the transcription factors Spi-B and PU.1. By investigating the mutational
signature profile in SNVs generated through the WES analysis of three matched tumournormal DNA leukemias, we gained insights on the basis of the mutagenic processes.
Leukemias generated in the absence of Spi-B and PU.1 have a strong enrichment of C•G
> A•T transversions which are commonly associated with 8-oxoguanine (8-oxo) DNA
damage. This finding indicates the potential involvement of reactive oxygen species
(ROS) in the generation of 8-oxo DNA damage, which consequently has the potential to
lead to leukemogenic events.

4.2
4.2.1

Results
Deletion of Spi-B And PU.1 is Strongly Associated With C•G
>A•T Genomic Transversions
The majority of the nucleotide alterations in the three tumour samples analyzed

(853, 854 and 857) were C•G > A•T transversions (Fig. 4.1). In order to gain further
insight into the mutational processes associated with leukemogenesis in the Mb1-CreDPB
mice, we determined the mutational signature of leukemias using DeconstructSigs
(Rosenthal, McGranahan, Herrero, Taylor, & Swanton, 2016). This package compares
the similarity of each tumour sample to a list of previous published signatures generated
by the analysis of 40 distinct types of human cancer (Alexandrov et al., 2013). This
analysis confirmed enrichment of C•G > A•T transversions in leukemias 853, 854 and
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857 (Fig. 4.2 A, B and C). We also observed an enrichment of C>A transversions flanked
5’base by either adenine (A), cytosine (C), guanine (G) or thymine (T) nucleotides. These
transversions were consistently flanked at the 3’ base by an adenine (A) nucleotide (Fig.
4.2 D).
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Figure 4. 1. Characterization of the Nucleotide Somatic Nucleotide Variants (SNVs)
Identified by Strelka Somatic Variant Caller in Three Mb1-CreDPB Mice Leukemias.
(A, B and C) SNVs distribution according to chromosome in leukemias isolated from
853, 854 and 857 mice, respectively. (D) Allelic frequency change for 853, 854 and 857
leukemias showing an enrichment for G>T and C>A substitutions.
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Chromosome

Figure 4. 2. Mutational Signature of Mb1-CreDPB Mouse Leukemias Shows Strong Bias
to C•G -> A•T Transversions.
(A-C) DeconstructSigs reconstruction analysis of mouse leukemias 853, 854 and 857.
COSMIC mutation signatures were used to reconstruct the mutational profile of mouse
leukemias and to predict similarity. (D) Heat map illustrating the mutational context of
5’ and 3’ nucleotides surrounding the transitions identified in samples 853, 854 and 857.
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Mutational signature analysis performed using DeconstructSigs indicated that the
signatures in leukemias 853, 854, and 857 were most similar to COSMIC Signatures 18,
24, 4, and 9. Signature 18, which showed the highest inferred weight for all leukemia
samples analyzed, has been also commonly observed in human childhood cancers
including B-ALL and neuroblastoma, but does not have a known mechanism (Alexandrov
et al., 2013). Signatures 4, 24 and 29 despite being enriched in distinct cancer types, also
exhibited a strong enrichment to C•G > A•T transversions. Interestingly, these signatures
have a common proposed etiology, indicating the presence of guanine damage that is
further repaired by transcription-coupled nucleotide-excision repair pathway (Table 3).
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Signature 29

Signature 24

Signature 18

Signature 4

Signature:

Gingivo-buccal oral squamous
cell carcinoma

Liver cancers

Commonly found in Neuroblastomas.
Breast and stomach carcinomas

Head and neck cancer, liver cancer, lung adenocarcinoma,
lung squamous carcinoma, small cell lung carcinoma, and
esophageal cancer.

Cancer Type:

Exhibits a very strong transcriptional strand bias for C>A
mutations indicating guanine damage that is being repaired
by transcription-coupled nucleotide excision repair.

Exhibits a very strong transcriptional strand bias for C>A
mutations indicating guanine damage that is being repaired
by transcription-coupled nucleotide excision repair.

The etiology of Signature 18 remains unknown.

Exhibits a very strong transcriptional strand bias for C>A
mutations indicating guanine damage that is being repaired
by transcription-coupled nucleotide excision repair.

Proposed Etiology:

Table 3. COSMIC Signatures Showing an Enrichment of C•G > A•T Transversions.
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4.2.2

Expression of DNA Glycosylases Mutyh, Neil3, Neil1 And Ogg1
Is Enhanced in Leukemias Generated in The Absence of Spi-B And
PU.1
Due to the high abundance of C•G > A•T transversions present in leukemias

extracted from thymic tumours of the Mb1-DPB mice, we asked whether the levels of
expression of the genes encoding DNA glycosylases were enhanced in leukemias lacking
Spi-B and PU.1. We took advantage of previous RNA-seq performed in six leukemias
extracted from Mb1-DPB mice to determine the levels of expression (by FPKM) of
Mutyh, Neil3, Neil1, Neil2 and Ogg1. For comparison, we reasoned that the levels of
expression of these genes in Pro-B cells could be used as reference. Therefore, we plotted
the levels of expression (FPKM) of non-leukemic Pro-B cells (i660BM) in which PU.1
has been either induced or not induced. The i660BM Pro-B cell line has become a useful
tool to study B cell development in the absence and in the presence of PU.1, as
doxycycline treatment for a period of 48 hours restores PU.1 levels, recovering the normal
developmental conditions of Pro-B cells. Therefore, PU.1 regulated genes such as Btk,
Blnk and Il7r were strongly induced upon doxycycline treatment after a period of 48
hours. As previously observed, Blnk, Btk and Spi1 were reduced in leukemias extracted
from the thymus of Mb1-CreDPB mice (Fig. 4.3 A). Therefore, these findings support the
use of i660BMPro-B cells as a reference control for normal gene expression during B cell
development.
The Mutyh gene was modestly increased in all leukemias compared to i660BM cells
induced (DOX) or non-induced (-DOX) with doxycycline. Strikingly, Neil1 expression
was enhanced ~6 fold in leukemias compared to Pro-B cells. Expression of Ogg1 and
Neil2 genes did not vary in leukemias compared to i660BM Pro-B cells. Interestingly,
although Neil3 expression was not changed in leukemias and Pro-B cells, the expression
of Neil3 was upregulated after PU.1 induction after doxycycline treatment (Fig. 4.3 B).
Overall the increase in Neil1 and Mutyh genes, point out to a possible involvement of
nucleotide-excision repair pathway facilitating the repair of 8-oxoG lesions.
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4.2.3

Generation of Reactive Oxygen Species (ROS) Leads to 8Oxoguanine Lesions Resulting in Leukemogenesis
The current understanding is that 8-oxoG damage is caused mainly by reactive

oxygen species (ROS) (David, O’Shea, & Kundu, 2007). ROS are produced as a
consequence of normal cellular metabolism in processes such as aerobic respiration. The
superoxide anion (O2 •-), is generated by enzymatic reactions of the mitochondrial
electron transport chain, NAD(P)H oxidase, xanthine oxidase and nitric oxide synthase
(NOS) among others (D’Autréaux & Toledano, 2007). In order to suppress the deleterious
effects of ROS, cells have evolved intricate antioxidant mechanisms. Superoxide
dismutase (SOD) enzymes are the first line of defense against ROS. Sod1 and Sod2 genes
encoding superoxide dismutase 1 and 2 respectively, dismutate the O2

•-

generating

hydrogen peroxide (H2O2) as product (D’Autréaux & Toledano, 2007). However, H2O2
is still mutagenic to cells, and can induce DNA single and double-strand breaks as well
as to DNA lesions through oxidation of nucleotides (Driessens et al., 2009). Thus, a rapid
antioxidative response, mostly mediated by enzymes such as catalase, peroxiredoxins
(Prxs), and glutathione peroxidases (GPx) takes place mediating catalysis of H2O2 to H2O.
Furthermore, the glutathione (GSH) system represents an essential defense mechanism
against oxidative stress. GSH interacts directly with ROS or to act as a cofactor for
glutathione peroxidases and GSH S-transferases. Oxidized GSH (GSHG) is converted
back to a reduced state by glutathione reductase. With these pathways in mind, we raised
the question of whether genes encoding superoxide dismutase (Sod1 and Sod2), as well
as genes encoding members of the GSH system, (Gpx1, Gss and Gsr), were upregulated
in Mb1-DPB mice leukemias compared to Pro-B cells.
Interestingly, while the levels of Sod2 were not changed, upregulation of Sod1
expression was observed in Mb1-DPB leukemias compared to Pro-B cells. Specifically,
leukemias 853, 854 and 857 all showed 2-fold upregulation of Sod1 expression compared
to expression in in Pro-B cells. Increased Sod1 levels has been observed in Down
Syndrome (DS) children since Sod1 gene is located on chromosome 21 (Pallardó et al.,
2006; Turrens, 2001). Importantly, susceptibility of developing myeloid, lymphoid or
megakaryocyte leukemia is increased significantly in DS children (Taub, 2001).
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Surprisingly, the gene encoding glutathione peroxidase 1, Gpx1, which catalyzes the
reaction that converts H2O2 to H2O also generating oxidized glutathione (GSHG), was
reduced in leukemias in comparison to Pro-B cells. In line with that, Gsr gene which
encodes glutathione reductase was also reduced in Mb1-DPB leukemias (Fig. 4.3 C).
These preliminary findings indicate that potentially there is an accumulation of H2O2
within leukemia cells, associated with impaired ability to neutralize antioxidant
mechanisms mediating the conversion of H2O2 to H2O.
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Figure 4.3. RNA-Seq Analysis of Six Thymic Leukemias Extracted from Mb1-CreDPB
Mice.
RNA-seq data from i660BM cells where PU.1 was induced (DOX+) or not induced
(DOX-) using doxycycline administration. (A) Heat map showing gene expression levels
(FPKM) of B cell related genes (left), graph shows FPKM levels of Spi1, Btk, Blnk and
Il7r in DOX+, DOX- and Leuk samples (right). (B) Heat map showing gene expression
levels (FPKM) of 8-oxoguanine glycosylases (left), graph shows FPKM levels of Ogg1,
Neil1, Neil2, Neil3, Mutyh in DOX+, DOX- and Leuk samples (right). (C) Heat map
showing gene expression levels (FPKM) of ROS responsive genes (left), graph shows
FPKM levels of Sod1, Sod2, Gss, Gsr, Gxp1 in DOX+, DOX- and Leuk samples (right).
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4.3 Discussion
We observed that leukemias originating in mice that lack of Spi-B and PU.1
present a high mutational spectrum, each tumour having over two thousand SNVs. These
data led us to explore the possible mechanisms by which this high mutational load is
generated. The mutational signature profile of these leukemias revealed an enrichment of
C•G > A•T transversions, pointing towards the possible involvement of ROS in the
generation of 8-oxoG DNA damage in the absence of the ETS transcription factors SpiB and PU.1. These findings raise the question of which cellular processes are altered in
the absence of Spi-B and PU.1 that could lead to DNA damage in consequence of ROS
production.
The link between ROS generation and human leukemias has been previously
addressed in a few studies. In a recent study, tumours from human pediatric cancers,
including 689 B-ALLs, showed that 12% of B-ALL possessed a mutational profile
containing the 8-oxoG damage signature, T-8 (ROS; COSMIC S-18) (Ma et al., 2018).
Interestingly, 36% of neuroblastoma tumours, a disease which the mutational signature
profile not yet associated with any known etiology, exhibited the 8-oxoG damage
signature at the age of diagnosis (Ma et al., 2018). Analysis of the mutational spectrum
of Down Syndrome AMkL leukemias with Gata1 mutations, also showed an elevated
number of C•G > A•T mutation suggesting that early leukemogenic events could be
related with oxidative stress (Cabelof et al., 2009).
During development of B cells, ROS derived from metabolism is drastically
increased at the Large Pre-B cell stage and decreases at the Small Pre-B cell stage (Stein
et al., 2017). At the Large Pre-B cell, highly proliferative B cells execute the switch to a
resting stage of Small Pre-B cell, by shutting down the IL-7R signaling via the signaling
downstream of the Pre-BCR (Clark et al., 2014). We have shown, in Chapter 2, that
developing B cells lacking Spi-B and PU.1 do not develop further than the Large Pre-B
cell stage. In Chapter 3, we demonstrated that leukemias originated from Mb1-CreDPB
mice are dependent in IL-7R signaling and are originated from Pro-B to Large Pre-B cell
stages. Therefore, this led us to hypothesize that IL-7R signaling dependency in the lack
of Spi-B and PU.1 leads to an extended period of ROS load, resulting in 8-oxoG damage
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resulting on the C•G > A•T mutational signature. However, we still need to determine 1)
whether the intracellular levels of ROS as well as the presence of 8-oxoG damage is
increased in developing B cells lacking Spi-B and PU.1 compared to normal cells and 2)
whether this damage is a consequence of the developmental block in a IL-7 signaling
dependent stage.

4.4

Material and Methods

4.4.1 Mice and Breeding
Mb1-Cre mice have been described previously (Hobeika et al., 2006). For this
study, Mb1-Cre mice were crossed with Spi1lox/lox Spib-/- to generate Mb1+/Cre Spi1lox/lox
Spib-/- mice (also referred to as Mb1-CreDPB mice). C57BL/6 mice were purchased from
Charles River Laboratories (Saint-Constant, QC, Canada). Mb1+/CreSpi1lox/lox Spib+/+
(referred to as Mb1-CreDP) and Mb1+/CreSpi1+/+ Spib-/- or Mb1+/+Spi1+/+ Spib-/- (referred
to as Mb1-CreDB) mice were used as experimental controls. Mice were fed with regular
chow and tap water ad libitum and housed with a 12-h light–dark cycle. Mice showing
signs of illness were euthanized and examined for spleen, thymus and lymph node
enlargement and analyzed as described below. All experiments were performed in
compliance with the Western University Council on Animal Care.

4.4.2 Cell Culture
The 660BM and i660BM cell lines used in this study were described previously.
Cells were cultured in IMDM (Wisent, QC, Canada) containing 5% IL-7–conditioned
medium from the J558L–IL-7 cell line, 10% FBS (Wisent), penicillin/streptomycin/Lglutamine (Lonza, Shawinigan, QC, Canada), 2-ME (Sigma-Aldrich, St. Louis, MO).
i660BM cells were maintained in 0.5 mg/ml puromycin (BioBasic, Markham, ON,
Canada). Cell lines were maintained in 5% CO2 atmosphere at 37 ̊C. For the RNAsequencing experiments i660BM cells were induced for 48 h with doxycycline (70 ng/ml)
in the presence of 5% IL-7–conditioned medium described above, and RNA was extracted
using an RNeasy Kit (QIAGEN, ON, Canada). Uninduced cells were used as a control.
Data analysis and processing has was performed as described previously (Batista et al.,
2017).
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4.4.3 RNA Sequencing
RNA was extracted from thymic tumours 853, 854 and 857 using RNeasy Kit
(QIAGEN, ON, Canada). RNA-sequencing was performed by McGill University and
Génome Québec Innovation Centre (Montreal, Canada). Paired-end (mRNA-sequencing
stranded) libraries were prepared using Truseq stranded total RNA library prep kit.
Libraries were sequenced using an Illumina HiSeq4000 PE100 instrument. Data analysis
was performed as described previously (Batista et al., 2017). In summary, Standard
Illumina sequencing adaptors were removed using Trim Galore!. Trimmed Fastaq reads
were aligned to the mouse reference genome version mm10 using TopHat2 (Trapnell et
al., 2012) in mate-paired mode using Galaxy suite. Assembled transcript abundance was
determined as previously using Cufflinks (Trapnell et al., 2012).
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Chapter 5

5

Discussion and Future Directions
The findings in this thesis address the mechanisms by which the transcription

factors Spi-B and PU.1 contribute to early B cell development and lineage progression,
and how the lack of Spi-B and PU.1 results in leukemogenic potential. We confirmed the
hypothesis that these transcription factors control events associated with transition from
high to low proliferation stages during the development of B cells, at the Pre-B cell stage
transition. We also identified events associated with leukemogenesis in mice with B cells
lacking Spi-B and PU.1. The data in Chapter 3 suggested that absence of these factors
favors a state of high proliferation, increasing significantly the leukemogenic potential of
developing B cells.
The experiments described in Chapter 2 assessed the function of PU.1 binding to
the Igk locus. PU.1 binding at this region has been observed before (Schwickert et al.,
2014; Whyte et al., 2013), but its function remained to be investigated. The levels of PU.1
remained constant following CLP commitment to the B cell fate suggesting an important
function during B cell development. Here we demonstrate that the binding to the Igk locus
is crucial to induce a state of genomic accessibility necessary for RAG rearrangements
and therefore progression to the Small Pre-B cell stage. Our pioneering observations that
PU.1 binds in close proximity to RSSs within the Igk locus, indicates PU.1 plays a role
in accessibility for RAG binding and therefore initiation of recombination events. In
summary, we established that the transcription factors Spi-B and PU.1 are required for
IgL recombination and transition to the Small Pre-B cell stage, independent of the
presence of the transcription factors IRF4 and IRF8.
We also observed that PU.1 and Spi-B deletion blocks B cell development in a
IL-7 dependent stage of Large Pre-B cells, and that this blockade can result in the
generation of leukemia overtime (Christie et al., 2015; Sokalski et al., 2011). In
experiments described in Chapter 3, we worked with the assumption that loss of PU.1 and
Spi-B were the ‘first hit’ for the initiation of leukemogenic events. In fact, we observed a
significant number of mutations in leukemias originated in the absence of these
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transcription factors, including mutations in known driver genes in human leukemias,
such as Jak3 and Ikzf3 genes. The mutational signature profile for these leukemias
(Chapter 4), also suggested that 8-oxoguanine damage is another initiator of mutagenic
events in the absence of Spi-B and PU.1.
Overall, we propose a working model whereby PU.1 and Spi-B function during B
cell development (Fig. 5.1). PU.1 and Spi-B were previously known to transcriptionally
control the expression of downstream components of Pre-BCR and BCR signaling such
as Btk, Blnk and Syk genes. Signaling through this pathway is required for the transition
from Large Pre-B cells to Small Pre-B cells, since it antagonizes IL-7R signals,
consequently enabling IgL recombination. We observed that PU.1 binds to the Igk
variable regions, as well as to Igk and Igl enhancers inducing transcription, a read-out of
accessibility for Ig recombination. We concluded that PU.1 binding is required to initiate
events leading to IgL recombination and therefore the progression to the Small Pre-B cell
stage.
We believe that three major events occur in the absence of PU.1 and Spi-B: 1)
Cells at the Pro-B cell/Large Pre-B cell stage are not able to terminate IL-7R signaling
due impaired Pre-BCR signals, 2) Large Pre-B cells are not able to start the events leading
to rearrangement of IgL genes, as a consequence of constant IL-7R signaling added to the
inability of binding of PU.1 in the Igk locus, and 3) Proliferative stress caused by IL-7
signaling dependency has the potential to cause 8-oxoguanine damage, alongside
oxidative stress, leading to mutations in genes conferring growth and survival advantages.
Therefore, PU.1 and Spi-B not only coordinate the B cell transition from high to low
proliferative stages and coordinates IgL recombination. The experiments performed in
Chapter 3, also revealed a role for PU.1 and Spi-B as tumour suppressors genes,
safeguarding the developing B cells against leukemogenic initiator events.

131

Figure 5.1. Proposed Model of Spi-B and PU.1 Function Controlling B Cell
Development and Leukemia Progression.
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5.1 PU.1 and Spi-B Redundancy and Function in B Cell
Development
The ETS family members PU.1 and Spi-B have redundant actions in developing
B cells due to two major observations: 1) the lack of only PU.1 or Spi-B does not cause
drastic impairments in B cell maturation (Sokalski et al., 2011) and 2) chromatin
immunoprecipitation analysis of PU.1 and Spi-B in B cells revealed a high degree of
binding overlap for these factors in the purine rich motif 5’ GGAA 3’(Solomon et al.,
2015). These observations bring to focus the importance of Spi-B and PU.1 in the
activation of a genetic program essential for B cell development.
Transcription factor redundancy is an evolutionary event linked with genomic
duplication events (Demuth & Hahn, 2009). If the transcription factor regulatory
redundancy is not resolved by mutations in the DNA binding domain resulting in slightly
different proteins regulating distinct set of genes, the redundancy is retained increasing
the network robustness allowing the transcription network to respond to diverse cellular
signals as well as to interact with other proteins (Gu et al., 2003). This seems to be the
case for Spi-B and PU.1, since Spi-B unique peaks are associated with ETS-IRF motifs
while PU.1 binding is associated with POU2F2 motifs (Solomon et al., 2015). Genes
regulated by overlapping transcription factors also have been noted to have increased
expression levels (Wu & Lai, 2015), leading us to speculate that overlapping transcription
factors work to guarantee the expression of “a critical genetic program” coordinating a
stage/context specific cell process. As the organism genetic complexity increases, there
is enhanced transcription factor redundancy in binding, associated with an increase in
fitness of individuals with redundancy (Rosanova, Colliva, Osella, & Caselle, 2017).
Despite their redundant functions, PU.1 and Spi-B expression levels have distinct
patterns during B cell development. While PU.1 expression remains constant through the
different stages of B cell development (Nutt et al., 2005), Spi-B levels are nearly
undetectable at the Pro-B cell stage achieving high expression levels at the Pre-B cell
stage, and increase significantly as B cells exit the BM (M. K. Anderson et al., 1999).
Thus, Spi-B and PU.1 transcription factors are both expressed at the Pre-B cell stage, a
stage in which we demonstrated that the lack of these factors results in a B cell

134

development blockade. Hence, our data together with the previous findings allow us to
conclude that Spi-B and PU.1 redundancy reinforces the genetic program required to the
transition from Large Pre-B cells to Small Pre-B cells during B cell development. The
constant expression of PU.1 during B cell development (Nutt et al., 2005) and PU.1
binding to the Igk locus (Schwickert et al., 2014; Whyte et al., 2013) have been observed
before by previous studies, although experimental data unrevealing the biological
significance of these results were lacking. We demonstrated here that PU.1 binding to the
Igk locus induces accessibility, a function previously attributed to the transcription factors
E2A and IRF4/8 (Lazorchak, Schlissel, & Zhuang, 2006; Lin et al., 2010). We have
shown that the absence of Spi-B and PU.1is sufficient to generate a developmental block.
We also established that PU.1 and Spi-B cooperate with IRF4/8 and E2A transcription
factors for Igk recombination at the Pre-B cell stage checkpoint.

5.2 Involvement of PU.1 and Spi-B in Human Leukemias
The absence of Spi-B and PU.1 transcription factors lead to Pre-B cell leukemia
with 100% of incidence in mice (Chapter 3, Fig. 3.1), however mutations in these
transcription factors are not a common event in human B-ALL. Mutations in SPI1 gene
is not associated with erythroleukemia or T cell leukemia, but is associated with human
AML. PU.1 expression is repressed by the protein product of the RUNX1-ETO
translocation, one of the most frequent chromosomal abnormalities in AML (Vangala et
al., 2003). Although, few studies have shown a correlation between the presence of
ETV6-RUNX1 translocation and decreased levels of Spi-B, in B-ALL. Spi-B shows to
be the top upregulated gene upon knockdown of endogenous ETV6-RUNX1 fusion gene
in two leukemia cell lines by using specific short hairpin RNAs (shRNA) (Fuka, Kauer,
Kofler, Haas, & Panzer-Grümayer, 2011). In a mouse model of ETV6-RUNX1 genes
related to Pro-B to Pre-B cell transition were downregulated including Blk, Blnk, CD19,
Ebf1, Foxo1, Irf4 and Spib (van der Weyden et al., 2011). The majority of the childhood
acute lymphoblastic leukemia abnormalities are frequently initiated by a chromosome
translocation event in utero (Malouf & Ottersbach, 2018). Taking into account that PU.1
deletion is embryonic lethal (Scott et al. 1994), this lethality could be a potential
explanation for the low frequency of Spi-B and PU.1 alterations in human leukemias.
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5.3 Transcription

Factors

as

Therapeutically

Targets

of

Malignancies
Transcription factors are commonly dysregulated in human pathogenesis such as
obesity, inflammation, cardiovascular disease, nervous system disorders, diabetes and
cancer (Papavassiliou & Papavassiliou, 2016). Tumour cells often have genes encoding
transcription factors amplified, deleted or rearranged by chromosomal translocations, or
genes that are subjected to point mutations resulting gain or loss of function (Bradner,
Hnisz, & Young, 2017). Mutagenesis events in transcription factors account for about
20% of oncogenes in cancer. Transcription factors often mutated in human leukemias
include the tumour suppressor p53 gene, the c-myb gene, the activator protein 1 (AP-1)
and the E26 transformation-specific transcription factors which mutations affect the status
of growth factor receptors such as epidermal growth factor receptor (EGFR) (Bradner et
al., 2017). Although gene-targeted treatment has emerged as a promising strategy for
cancer, only very few have been successfully approached by coordinated efforts in drug
discovery. A successful example, of modulation of an oncogenic transcription factor, is
the development of all-trans retinoic acid (ATRA) as therapy for acute promyelocytic
leukemia (APML). The first case of leukemia remission was reported in 1985, where a 5year-old girl with anthracycline-refractory APML was administered ATRA, and achieved
a complete long-term remission in combination with ATRA and chemotherapy (Z.-Y.
Wang & Chen, 2008). The interaction of ATRA with PML-RARA t(15;17) translocation
leads to a conformational change that disrupted its association with histone deacetylasecontaining corepressors in favor of acetyltransferase coactivators. Consequently, one of
the outcomes of ATRA binding to PML-RARA is its conversion from a repressor to an
activator of transcription, through the elevation of local histone acetylation at sites
occupied by PML-RARA (Bhagwat & Vakoc, 2015). One of the limitations of genetargeted therapy is that transcription factors are required in many cell types, thus targeting
this regulator has a risk-to-benefit ration of unspecific actions (Bhagwat & Vakoc, 2015).
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5.4 A Potential Parallel of Developmental Malignancies
Among childhood cancers, leukemia is the most frequently diagnosed, accounting
for 30% of all childhood cancers. Neuroblastomas, accounts for 6% of all childhood
cancers, and is the fourth most common cancer within this group (R. L. Siegel, Miller, &
Jemal, 2016). Neuroblastoma is a solid cancerous tumour that begins in the nerve cells.
It most often begins in the adrenal glands, but it can also develop in other areas of the
abdomen and in the chest, in the neck, and near the spine (Louis & Shohet, 2015). In
recent decades, cure rates for childhood cancers have increased to 80%, but cancer
remains the leading cause of death in children (C.-H. Pui, Gajjar, Kane, Qaddoumi, &
Pappo, 2011). Furthermore, harsh treatment methods such as chemotherapy, radiotherapy
and surgery can cause long-term adverse effects, mental disabilities, secondary cancers
and organ toxicity. Therefore, the development of less damaging therapies to treat
childhood cancers. Aiming to identify a distinct genetic repertoire in pediatric
malignancies, a recent study analyzed the landscape of genomic alterations in a cohort of
961 child tumours (Gröbner et al., 2018). Most of the tumours exhibited a mutation
signature enriched in C > T transitions (≥30% of SNVs in two-thirds of cancer types).
This pattern, mutational signature 1, is associated with reduced age. In addition, signature
18, associated with oxidative DNA damage and enriched to C>A transversions was
heterogeneously represented within several cancer types (Gröbner et al., 2018). Mutation
signature 18, was observed in leukemia tumours extracted from Mb1-CreDPB mice as
discussed in detail in Chapter 4. Altogether, these observations suggest the presence of a
potential shared mechanism responsible to driving tumourgenesis in children. Further
investigation of this topic is needed to clarify the events leading to development of these
two developmental cancer types.

5.5 Concluding Remarks and Future Directions
The work described in this doctoral thesis addresses two major aspects of
transcriptional regulation: 1) it emphasizes the importance of transcriptional regulation in
the progression of developmental events leading to the generation of mature cell types,
and 2) it highlights the potential generation of disease by transcriptional regulation
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disturbances. Particularly, the experiments described in this thesis illustrate the functions
of Spi-B and PU.1 transcription factors in the development of B cells and leukemogenesis.
Our findings bring into perspective the potential role of PU.1 and Spi-B in Igk
variable regions usage, since only half of the Igk variable genes were upregulated
transcriptionally upon PU.1 induction (Chapter 2). The selection of the Igk variable
regions that undergo recombination is still understudied, but evidence suggests that CTCF
zinc finger transcription factors also play a role mediating Igk contraction and appropriate
Vk usage (de Almeida et al., 2015). The preferential binding of PU.1 in certain Igk
variable genes, brings attention to the genomic features responsible for preferential
binding and its implications. Therefore, we hypothesize that PU.1 binding has the
potential to favor the selection of certain variable regions. Another interesting observation
was the close proximity of PU.1 binding with the presence of RSSs (Chapter 2, Fig 2. 5).
Thus, data reanalysis of ChIP-seq datasets of RAG-1/2, PU.1 and Spi-B in Pro-B cells
provides a useful method to further investigate the existence of a binding overlap among
these factors in bigger genomic datasets. The correlation between the binding of these
factors into genomic regions enriched for H3K4me3 would strongly indicate that PU.1
and Spi-B function as pioneer transcription factors mediating accessibility of certain Igk
variable genes.
Our second major observation was that the generation of leukemia was associated
with driver mutations in Janus Kinases genes. Although our data indicates that driver
mutations in Jak3 gene are enough to generate leukemia in the absence of Spi-B and PU.1
(Chapter 3), we cannot rule out the possibility that mutations in other genes could
synergize leukemogenic events. In addition, it is possible that the presence of multiple
drivers increases leukemia fitness conferring morphologic and metabolic changes acting
in combination to the survival and proliferative advantages conferred by Jak3 mutations.
Some aspects regarding the molecular mechanisms associated with leukemogenesis in the
absence of Spi-B and PU.1, need to be further investigated. We hypothesized that ROS
leads of 8-oxoG genomic damage, consequently leading to C•G > A•T transversions
observed in high frequency in leukemias lacking Spi-B and PU.1 (Chapter 4). These
studies need to be experimentally validated as discussed in Chapter 4. The advantage of
generating a mouse model resembling aspects of human leukemia - such as leukemias
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associated with Down Syndrome and Ph-like leukemia, brings the potential to study the
events leading to leukemogenesis, in addition to testing of new chemotherapies.
In summary, our studies shed light on several unknown aspects of PU.1 and SpiB biology, specifically at their stage-specific function in B cell development and the
mechanisms by which dysregulation of these factors generates leukemia. Our work also
brought into perspective the broad roles of PU.1 and Spi-B in B cell physiology. By
controlling the expression of a distinct set of genes, Spi-B and PU.1 transcription factors
are able to promote B cell maturation by executing transition from high proliferative to a
quiescent stage in B cell development.
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